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Handbook of Intelligent Scaffolds for Tissue Engineering and Regenerative Medicine. 












surrounding	matrix	to	guide	cells	towards	a	certain	phenotype3, 4. Among the most important 
extracellular	 matrix	 components	 are	 collagen	 fibrils,	 elastic	 fibers,	 glycosaminoglycans	 and	
growth factors.
Table 1; Characteristics of elastin, collagen and glycosaminoglycans.
*  With strong variation in molecular structure within one molecule (HS: heparan sulfate, DS: dermatan 
sulfate, CS: chondroitin sulfate)5.  
# With some variation in size6.
Collagen
Collagen is the most abundant protein in the body making up about 30% of the body’s dry 
weight.	Over	29	different	types	of	collagen	have	been	identified,	types	I-V	being	quantitatively	
the most important6.	 In	 all	 organs,	 collagen	 forms	 the	basic	matrix	material,	 type	 I	 collagen	
being	the	main	fibrillar	collagen	of	bone,	tendon	and	skin.	The	type	I	collagen	is	a	rod	(1.5	x	300	
nm) with a molecular mass of about 300 kDa, 90% of all collagen is type I. Collagen has adhesive 
properties	and	its	degradation	products	have	chemotactic	characteristics7. 
Elastin    
Elastin	 is	a	highly	hydrophobic	protein	which	provides	elasticity	to	tissues	 like	skin,	 lung	and	
blood vessels8.	Tropoelastin	molecules	and	microfibrils	are	crosslinked	to	each	other,	forming	









Glycosaminoglycans	 (GAGs)	 are	 long,	 linear	 and	 highly	 negatively	 charged	 polysaccharides	
which	 are	 covalently	 bound	 to	 core	 proteins	 (proteoglycans)	 in	 the	 extracellular	matrix	 and	
cell surfaces15. Based on their backbone structure, four major classes of GAGs are formed, viz. 
heparan	sulfate/heparin,	dermatan/chondroitin	sulfate,	keratan	sulfate	and	hyaluronate.	GAGs	
mediate	many	biological	 functions,	 in	part	by	their	capacity	to	bind	and	modulate	a	number	




them	valuable	molecules	to	be	incorporated	into	tissue	engineered	constructs17.  GAGs can be 
incorporated	in	constructs	by	crosslinking	and	their	significance	in	angiogenesis	and	the	wound	
healing has been demonstrated18-20.
Growth factors
Growth factors are signal molecules that regulate many aspects of cell behaviour like growth, 
differentiation	and	survival.	Growth	factors	can	enhance	biological	processes	like	the	formation	
of	blood	vessels	 (e.g.	by	VEGF	 (vascular	endothelial	 growth	 factor)),	 and	 the	proliferation	of	
certain	types	of	cells	like	keratinocytes	by	FGF-7	(keratinocyte	growth	factor)	and	fibroblasts	by	
FGF-2	(basic	fibroblast	growth	factor)21.	The	extracellular	matrix	serves	as	a	reservoir	for	growth	
factors	protecting	 them	against	proteolytic	degradation.	Growth	 factors	 are	able	 to	bind	 to	
glycosaminoglycans and a sustained release enhances biological processes. Growth factors 
such	as	FGF2	and	VEGF	can	be	used	in	tissue	engineered	constructs	to	enhance	angiogenesis	
and	tissue	formation22, 23.
Scaffolds with defined molecular composition: isolation procedures and construction
Complex	 scaffolds	with	 a	 predefined	 composition	 can	 be	 prepared	when	purified	 individual	
components	 are	 available.	 Only	 in	 this	 way,	 one	 can	 systematically	 study	 the	 effect	 of	 the	
single	components	on	tissue	response	 in vivo.	 Insoluble	type	I	collagen	fibrils	can	be	purified	
from	bovine	 achilles	 tendon	 using	 extractions	with	 diluted	 acetic	 acid,	 NaCl,	 urea,	 acetone,	
and demineralised water24.	 Insoluble	 elastin	 fibres	 can	 be	 isolated	 from	equine	 ligamentum	











Glycosaminoglycans	 (heparan	 sulfate	 from	 bovine	 kidney	 and	 chondroitin	 sulfate	 from	
bovine	 trachea)	 can	 be	 purified	 using	 papain	 digestion,	 alkaline	 borohydride	 treatment,	
diethylaminoethyl	cellulose	(DEAE)	ion-exchange	chromatography,	and	glycosidase	digestion26. 
Isolated glycosaminoglycans are characterized by agarose gel electrophoresis27	and	quantified	
using	a	modified	Farndale	assay28.	Growth	factors	are	produced	in	milligram	quantities	using	
recombinant	DNA	technology	and	purified	using	affinity	chromatography,	as	demonstrated	e.g.	
for vascular endothelial growth factor (VEGF)29	and	fibroblast	growth	factor	2	(FGF2)23. 
Crosslinking and covalent attachment of glycosaminoglycans
Crosslinking	 of	 scaffolds	 will	 make	 them	more	 resistant	 to	 degradation	 and	 increases	 their	
mechanical stability. A commonly used crosslinker is 1-ethyl-3-(3-dimethyl aminopropyl) 
carbodiimide	(EDC)	in	combination	with	N-hydroxysuccinimide	(NHS),	which	creates	zero-length	
crosslinks	introducing	only	an	amide	bond.	The	strength	of	the	scaffold	and	the	biodegradation	
can	be	varied	by	the	crosslinking	condition26, 30.  Glycosaminoglycans can be bound to lyophilized 
scaffolds	 in	 the	 crosslinking	 step,	 thereby	 covalently	 attaching	 them	 to	 the	 scaffold26. When 
crosslinking	 glycosaminoglycans,	 such	 as	 chondroitin	 sulfate,	 to	 collagen	 scaffolds,	 growth	
factors can be bound and modulated23 and also the water-binding capacity increases over 50%19. 





heparin-binding epidermal growth factor (hbEGF), placental growth factor (PlGF)17. When 
growth	factors	are	bound	to	the	scaffold	by	glycosaminoglycans,	a	more	sustained	release	is	
found23. 
Scaffolds with a specific three-dimensional structure








IV collagen, heparan sulfate proteoglycan, and laminins32.	Compact	collagen	films	(Fig.	1A)	can	
be	prepared	by	air-drying	a	homogenized	and	de-aerated	collagen	suspension	in	diluted	acetic	







Figure 1. Macroscopic (A, B) and scanning electron microscopical images (C, D) of dense films (A, C) and 










a	 suspension	of	 collagen	and	elastin19.	More	 specifically,	a	 collagen	 (with	or	without	elastin)	
suspension	 in	 diluted	 acetic	 acid	 is	 applied	 to	 a	mould,	 frozen	 and	 lyophilized,	 resulting	 in	
porous	 scaffolds.	 The	 pore	 structure	 observed	 after	 freeze-drying	 resembles	 the	 ice	 crystal	
network formed during the freezing process. By varying the freezing temperature, and hence 




freezing at -20°C. 
Figure 2. Scanning electron micrographs of porous collagen scaffolds prepared by freezing and lyophilisation 
of an acidic collagen suspension. Pore size can be influenced by the freezing temperature. Use of relatively 
high freezing temperature (-20°C), resulted in larger ice crystals compared to those obtained with lower 
freezing temperatures (-80 or -196°C). The insets in B and C show lamellae with interconnecting struts. Bars 
are 100 µm, bars in inserts are 20 µm. Figure reproduced from Faraj et al. 200731 with permission.  
Scaffolds for skin tissue engineering
The	construction	of	scaffolds	with	a	defined	morphology	and	molecular	composition	allows	the	
preparation	of	constructs	that	mimic	the	micro-environment	of	normal	tissue.	These	constructs	
are designed in such a way that they give the correct signals to the cells to migrate into the 
scaffold	and	regenerate	the	desired	tissue.	Due	to	the	defined	morphology	and	composition	the	
contribution	of	each	component	can	be	evaluated	in vitro and in vivo.	The	knowledge	acquired	
with this approach makes it possible to design and develop constructs to replace and/or repair 
tissue.	One	application	is	skin.








1Regeneration	 of	 the	 epidermis	 starts	 at	 the	 wound	 edges	 and	 from	 the	 remaining	 dermal	
appendages37.	In	full-thickness	wounds,	the	entire	epidermis	and	dermis	are	destructed,	leaving	
no residual epidermal cells for wound closure from underneath.
The	golden	standard	to	close	large	burn	wounds	is	still	transplantation	of	autologous	split	skin,	









often	need	a	 two	 stage	operation	procedure	 (e.g.	 IntegraDRT)41, 42	 and	 still	 result	 in	 scarring	
and	contractures.	 In	addition,	they	are	poorly	characterised	with	respect	to	the	components	
present,	 and	 this	 seriously	 hinders	 the	 identification	of	 the	 biological	 relevant	molecules	 to	






















assessed	 in	a	subcutaneous	rat	model	with	specific	 focus	on	blood	vessel	 formation.	Finally,	
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Large-scale	 production	of	 recombinant	 rat	 vascular	 endothelial	 growth	 factor	 (rrVEGF-164)	 is	 




AOX1	promoter,	was	 constructed.	 The	methylotrophic	 P.	 pastoris	was	 used	 as	 the	 eukaryotic	 
expression	 system.	 After	 transformation,	 rrVEGF-	 164	 was	 produced	 by	 fermentation	 (≈124	
mg/L)	and	purified	by	heparin	affinity	chromatography.	SDS–PAGE	indicated	that	rrVEGF-164	was	
produced	as	a	disulphide-bridged	dimer	of	48	kDa	which	was	purified	 to	near	homogeneity	by	 
heparin	 affinity	 chromatography	 in	 a	 large	 quantity.	 A	 bioassay	 indicated	 a	 three-	 to	 fivefold	 
increase	 in	 endothelial	 cell	 proliferation	 after	 3	 days,	 due	 to	 the	 addition	 of	 the	 produced	
rrVEGF-164.	The	produced	rrVEGF-164	showed	a	higher	biological	activity	than	a	commercially	
available,	mouse	cell	 line-based,	growth	 factor.	 In	conclusion,	using	 the	P.	pastoris	expression	
system	we	were	able	to	produce	biologically	active	rat	VEGF-164	in	high	quantities	and	this	may	






Vascular endothelial growth factor (VEGF)2 is one of the most celebrated mediators in the 
process	of	angiogenesis.	VEGF	 is	a	hypoxia-	 inducible	protein	 that	promotes	 the	proliferation	
and survival of vascular endothelial cells1.	At	 least	five	different	rat	VEGF	alternatively	spliced	 
isoforms	have	been	identified	originating	from	a	single	VEGF	pre-mRNA:	VEGF-120,	-144,	-164,	
-188 and -2052–4. These isoforms resemble the human VEGF isoforms (VEGF-121, - 145, -165, 
-189	and	-206)	and	differ	in	length	from	them	by	one	amino	acid.	VEGF	is	only	active	in	its	dimeric	
form5,6.	All	rat	VEGF	isoforms	are	mitogenic	to	vascular	endothelial	cells	and	induce	permeabilisation	





a layer around the sprout10,11.	Large-scale	production	and	purification	of	rat	VEGF-164	is	desirable	
for	angiogenic	studies	in	vitro	and	in	vivo,	especially	in	rat	animal	models	for	tissue	engineering	
in which enhanced angiogenesis is an issue. Since the source of natural (rat) growth factors is 
limited,	attempts	have	been	made	to	produce	growth	factors	on		a	large-scale	by	recombinant	
DNA technology. Growth factors have been produced in Escherichia coli and have played an impor-
tant role in basic research of rat angiogenesis12,13.	E.	coli	is	a	prokaryote	and	its	intrinsic	characteristics	 
such	 as	 protein	 processing,	 protein	 folding,	 and	 post	 translational	modifications,	 differ	 from	







the	P.	pastoris	yeast	cells.	 rrVEGF-164	was	secreted	 in	 large	quantities,	purified	using	heparin	 
affinity	chromatography,	and	 its	biological	activity	was	studied	 in	vitro	using	human	umbilical	









Unless stated otherwise, all materials were from Merck (Darmstadt, Germany). The VEGF 
upstream (50-GTA GAA TTC GCA CCC ACG ACA GAA GG-30) and VEGF downstream (50-TAT GCG 
GCC	GCT	CAC	CGC	CTT	GGC	TTG	T-30)	primer	containing	EcoRI	and	NotI	restriction	sites	were	
synthesised	by	 Isogen	Biosciences	BV	 (Maarssen,The	Netherlands).	 The	P.	pastoris	 expression	




Laboratories, Detroit, MI, USA), containing 10 g glucose and 0.1 g ampicillin (Sigma Chemical Co., 
St.	Louis,	MO,	USA).
Buffered Glycerol-complex Medium (BMGY) containing glycerol as the carbon source, consisted 
per	litre	of:	10	g	yeast	extract,	20	g	peptone,	21.2	g	potassium	sulphate	(pH	6.0),	13.4	g	yeast	
nitrogen	base	(YNB)	(Sigma),	0.4	mg	biotin	and	10	ml	glycerol.
Buffered Methanol-complex Medium (BMMY)	 is	 similar	 to	 BMGY,	 but	 with	 5	 ml	 methanol	 
instead of glycerol. Basal saltsmedium(BSM) consisted per litre of: 26.7mL phosphoric acid, 
1.18	g	calcium	sulphate•2H2O,	18.2	g	potassium	sulphate,	14.9	g	magnesium	sulphate•7H2O,	
4.1	g	potassium	hydroxide	and	40	ml	glycerol.




U penicillin and 0.1 g streptomycin (Gibco BRL, Carlsbad, Ca, USA).
YNB dropout plates	 consisted	per	 litre	of:	6.7	g	YNB,	1.92	g	 yeast	 synthetic	dropout	medium	
supplement (Sigma), 20 g glucose and 20 g agar (Gibco BRL).
TYE agar plates	consisted	per	litre	of:	8	g	NaCl,	10	g	peptone,	5	g	yeast	extract,	15	g	agar	(Gibco	
BRL), 10 g glucose and 100 g ampicillin (Sigma).







1	mM	deoxynucleoside	 triphosphates	 (dNTPs)	and	10	mM	DTT	 (Gibco	BRL)	 in	a	 total	 volume	
of 20 µL.	PCR	fragments	of	the	full-length	cDNA	were	prepared	with	10	mM	Tris–HCl	(pH	8.3)	





polymerase (Promega) in a total volume of 50 µL.	The	PCR	was	performed	on	a	Peltier	Thermal	
Cycler (PTC-200; MJ Research and Biozym, Landgraaf, The Netherlands), with a 30 cycles program 
(95 °C for 60 s, 65 °C for 60 s, 72 °C	for	90	s	and	extension	at	72	°C for 5 min). The rrVEGF-164 
cDNA	was	isolated	from	a	2%	(w/v)	agarose	gel	and	purified	with	a	QIAEX	II	gel	extraction	system	
(QIAGEN, Hilden, Germany). The SMART-ladder marker (Eurogentec Seraing, Belgium) was used 
to	estimate	the	sizes	of	the	PCR	products.
Construction of expression vector
The	purified	cDNA	was	subcloned	into	the	vector	pPIC9HV	(J.M.H.	Raats,	Dept.	of	Biochemical	
Chemistry, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, unpub-
lished	data	(pPIC9	expression	plasmid	was	obtained	from	Invitrogen))	after	digestion	with	EcoRI	
and	NotI	 (Invitrogen)	 in	 the	presence	of	1x	React®	3	buffer	 (Gibco	BRL)	 for	1	h	at	37	°C. The 
pPIC9HV is similar to the original pPIC9 vector17,18,	but	contains	a	polyhistidine	and	VSV	tag	for	
detection	and		purification.	The	rrVEGF-164	insert	was	ligated	into	pPIC9HV	vector	DNA	using	T4	
ligase	(Gibco	BRL)	in	T4	ligase	buffer	(Gibco	BRL)	for	24	h	at	16	°C. The host strain E. coli (supE44 
DlacU169 (a80lacZDM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1) was transformed with the 





selected	and	suspended	in	LB-medium.	After	24	h	incubation	at	37	°C at 200 rpm in an orbital 
shaker, the suspension was centrifuged for 1 min at 14,000g. Plasmid DNA was isolated using the 
QIAprep	spin	miniprep	kit	(QIAGEN)	according	to	the	manufacturer’s	instructions,	and	positive	
transformants	were	 identified	by	automated	 sequencing	using	 an	a-factor	primer	 (50-ACTAC-
TATTGCCAGCATTGCTGCT-30)	at	the	DNA	Sequencing	Facility,	Dept.	of	Human	Genetics,	Radboud	
University Nijmegen Medical Centre, The Netherlands.
Transformation into P. pastoris yeast cells
Pichia	pastoris	GS115	cells	were	grown	in	100	ml	YPD-medium	overnight	at	30	°C at 200 rpm in 
an	orbital	shaker,	until	an	OD600	of	1.5	was	reached,	which	corresponds	to	a	cell	density	of	ap-
proximately	109	cells/ml.	Competent	GS115	cells	were	freshly	prepared	before	transformation	
by	 consecutive	washings	with	 ice-cold	 sterile	MilliQ	water	 and	1	M	 sorbitol	 according	 to	 the	
Invitrogen	manual.	The	DNA	was	linearised	by	digesting	10	µg of plasmid DNA with SalI. Subse-
quently,	the	linearised	DNA	was	purified	using	the	QIAGEN	PCR	cleanup	kit.	To	transform	the	P.	
pastoris	yeast	cells	with	the	expression	vector,	cells	were	resuspended	in	1	M	sorbitol	on	ice,	and	
80 µL of competent cells were electroporated by means of pulse discharges (1.5 kV, 25 µF,	400	X,	
Bio-Rad Gene Pulser, CA, USA) for 9 ms in the presence of 10 µg linearised plasmid DNA (20 µL). 
After		electroporation,	cells	were	put	on	ice	for	5	min,	10x	diluted	in	1	M	sorbitol	and	incubated	for	












containing	25	ml	BMGY-medium	for	an	overnight	period	at	30	°C at 200 rpm in an orbital shaker. 
To store the cultures, frozen stocks were prepared by adding 60% (v/v) glycerol (0.5 ml) to the 
P.	pastoris	recombinants	in	YPD-medium	(0.5	ml)	and	freezing	at		-80	°C.
Expression screening of rrVEGF-164




(1500g, 4 °C,	 10	min)	 and	 resuspended	 in	 BMMY-medium	 containing	 25%	 (v/v)	methanol	 as	
the major carbon source. Cells were incubated for 2 days at 30 °C, 200 rpm in an orbital shaker. 
After	centrifugation	(1500g,	4	°C, 10 min), the secreted rrVEGF-164 was concentrated from the 
supernatant by adding 50 µl heparin-acryl beads (Sigma Chemical Co.) to 1 ml supernatant, 
and	incubation	for	1	h	at	21	°C	under	rotating	conditions.	Heparin	beads	were	concentrated	by	 
centrifugation	(1500g,	4	°C,	10	min)	and	analysed	using	SDS–PAGE	and	Western	blotting	analysis	
as described below. 
Large-scale production of rrVEGF-164
For	large-scale	rrVEGF-164	production,	a	1	L	baffled	flask	with	200	ml	YNB-medium	was	inoculated	
with	 1	ml	 thawed	P.	 pastoris	 host	 strain	GS115	 containing	 the	 rrVEGF-164	expression	 vector.	
An overnight culture was incubated at 30 °C	at	200	rpm	in	an	orbital	shaker	until	an	OD600	of	 
approximately	6	was	reached.	The	Bioflo®3000	fermentor	(New	Brunswick	Scientific,	Edison,	NJ,	
USA), containing 2 L of basal salts medium, was sterilised by autoclaving for 45 min at 121 °C. 
After	 autoclaving,	 4.35	 ml/L	 PTM1	 trace	 salts	 (Sigma)	 were	 added	 aseptically	 to	 the	 initial	 
fermentation	volume.	Ammonium	hydroxide	(28%	(w/v),	Sigma)	was	used	as	a	nitrogen	source	
and	to	increase	the	pH	during	the	fermentation	process.	The	200	ml	inoculum	was	transferred	
into	 the	 fermentor	 after	 setting	 the	 dissolved	 oxygen	 (DO)	 at	 100%,	 the	 pH	 at	 6.0	 and	 the	 













at 30% for another 30 h. The culture was then harvested and centrifuged (20 min at 5000g). 
The	supernatant	was	filtered	using	a	0.45	lm	cellulose	acetate	membrane	filter	(Schleicher	and	
Schuell,	Dassel,	Germany)	and	dialysed	against	10	mM	phosphate	buffered	saline	(pH	7.4).	




HiTrapTM column (Amersham Biosciences, Stockholm, Sweden). The rrVEGF-164 was eluted 
with 1 M NaCl in 10 mM PB (pH 7.0) for 20 min, followed by 2 M NaCl in 10 mM PB (pH 7.0) for 
20	min	at	2.5	ml/min	for	both	solutions	(see	Fig.	5).	Five	fractions	(2.5	ml/fraction)	with	highest	
A280 absorbance were collected, pooled and directly frozen at -80 °C. 
Purity	 and	 dimer	 formation	 were	 evaluated	 by	 sodium	 dodecyl	 sulphate	 polyacrylamide	 gel	 
electrophoresis	(SDS–PAGE;	15%	(w/v);	Serva	GmbH,	Frankfurt,	Germany)20.
Briefly,	the	supernatant	was	diluted	1:1	with	sample	buffer	with		and	without	5%	(v/v)	b-mer-
captoethanol	(with	and	without	reducing	conditions)	and	denatured	for	5	min	at	95	°C. Then 10 
µl (±0.6 µg) of denatured rrVEGF-164 was loaded on the gel and was visualised by Coomassie 
brilliant	blue	(0.1%	(w/v))	staining	or	further	identified	by	Western	blotting	using	goat	anti-rat	
VEGF	antibody	(1:1000)	(R&D	Systems)21.	The	amount	of	purified	rrVEGF-164	was	determined	by	
a Lowry analysis using bovine serum albumin (BSA) as a standard22.
Biological activity of produced rrVEGF-164 
Human umbilical vein endothelial cells (HUVECs, ATCC, CRL- 1730, Rockville, MD, USA) were 
grown in F12K medium (Gibco BRL) with 20% (v/v) fetal calf serum (FCS), 1.5 % (w/v) calf brain 
extract	 (as	 a	 source	 for	 endothelial	 cell	 growth	 factor	 (ECGF)),	 0.14	mg/ml	heparin,	 200	mM	














Fig. 1. Agarose gel electrophoresis of PCR products. (A) Ethidium bromide-stained agarose gel shows in lane 1: 
DNA marker, lane 2: PCR products after amplification using VEGF specific primers, indicating three VEGF splice 
variants, VEGF-188 (564 bp), VEGF-164 (492 bp) and VEGF-120 (360 bp). (B) Lane 1: DNA marker, lane 2: the 
rrVEGF-164 insert (492 bp) and in lane 3 the pPIC9HV vector (8580 bp). 
Fig. 2. Map of the rrVEGF-164 expression vector based on the pPIC9HV vector. MCS: multiple cloning site. The 
a-factor directs VEGF to the secretory pathway. EcoRI and NotI restriction sites were used to insert rrVEGF-164 
into the multiple cloning site. The ampicillin resistance gene (AMP) was used for E. coli transformant selection. 
The histidine independent gene (His4) allows growth in the absence of histidine, and was used for P. pastoris 
transformant selection. The SalI restriction site was used to inactivate the His4 gene and only a successful ligation 





Fig. 3. Nucleotide sequence and the deduced amino acid sequence of the relevant part of P. pastoris rrVEGF-164 
expression vector, indicating a-Factor Signal Sequence, the EcoRI restriction site, the rVEGF-164 insert, the NotI 
restriction site and the polyhistidine-VSV tag. A stop codon was positioned between rVEGF-164 and NotI in order 
to produce VEGF without tags. The a-factor signal, the rVEGF-164, and the His/VSV tag are indicated by boxes. 
The a-factor primer is also indicated.
Results and discussion
Preparation of rat VEGF-164 cDNA
Total	RNA	was	 isolated	 from	embryonic	R.	norvegicus	tissue	and	 transcribed	 into	cDNA	using	
random	hexanucleotide	primers.	After	amplification	with	VEGF	specific	primers,	PCR	products	











Construction of expression vector






homology	with	 the	 nucleotide	 sequence	 of	 rrVEGF-164	 published	 by	 Conn	 et	 al.24 (Genbank 
reference AAA41211) and Strausberg et al.25	(Genbank	reference	AAI68708).	Cloning	and	production	
of	rat	VEGF-164	After	isolation	and	linearisation	of	the	plasmid	DNA	of	the	positive	clone	with	




Fig. 4. Profile of fermentation process describing the % methanol feed, pH, % dissolved oxygen level and % 
glycerol feed in time (hours). In the culture phase a biomass of yeast cells was formed. In the fed-batch phase 
glycerol was accumulated in the yeast cells as a major carbon source. In the induction phase the VEGF-164 
production was induced with methanol. 
Purification and identification of rrVEGF-164
From	the	small	production	screening	one	clone	with	a	strong	band	on	Western	blot	was	selected	 
and	used	 for	 large-scale	production.	After	 the	 fermentor	 run,	 the	bulk	cell	mass	was	separated	








Using	non-reducing	 conditions,	 SDS–PAGE	 showed	one	broad	band	of	 about	 48	 kDa	 (dimer),	
whereas	under	reducing	conditions	a	main	band	of	about	24	kDa	band	(monomer)	was	observed	
(Fig.	 6A).	 It	was	 to	be	expected	 that	on	a	 SDS–PAGE	gel	 dimeric	 and	monomeric	 rrVEGF-164	
migrate	at	45	kDa	and	23	kDa,	respectively26.	Western	blot	analysis	using	an	anti-rat	VEGF-164	
antibody	 further	 indicated	 that	 the	 protein	 was	 rat	 VEGF-164	 (Fig.	 6B).	 Under	 non-reducing	 
conditions,	 the	expressed	 rrVEGF-164	existed	 in	 the	biologically	active	 form	of	a	homodimer.	
Dimers	of	VEGF	are	disulphide-bridged,	which	is	essential	for	the	biological	activity	of	VEGF-1645. 
These data indicate that rrVEGF-164 is produced as a disulphide-bridged dimer which can be 
purified	to	near	homogeneity	by	heparin	affinity	chromatography.
Fig. 5. FPLC flow chart of the 
purification of rrVEGF-164 by 
heparin affinity chromatography. 
In green the elution buffers are 
indicated; viz. 10 mM phosphate 
buffer (pH 7.0) containing 1 M 
NaCl or 2 M NaCl. The Y-axis 
indicates absorbance λ = 280 
nm expressed in arbitrary units 
(AU). On the X-axis, the collected 
fractions (each containing 2 ml) 
are represented by the vertical 
dashed lines. (For interpretation 
of the references to colour in 
this figure legend, the reader is 
referred to the web version).
Biological activity of produced rrVEGF-164
The	biological	activity	of	the	purified	rrVEGF-164	was	determined	by	a	WST-1	proliferation	assay	
using	human	endothelial	cells	(HUVECs).	HUVECs	are	generally	used	to	evaluate	the	activity	of	
VEGF from various species16,27.	Already	after	1	day,	the	25	ng/ml	content	resulted	in	a	threefold	
increase	in	proliferation	compared	to	medium	without	added	VEGF	(Fig.	7A).	After	3	days,	the	
amount	of	proliferation	at	content	of	12.5–25	ng/ml	showed	a	three-	to	fivefold	increase	(Fig.	7B).	











Fig. 6. Analysis of produced 
rrVEGF-164 by SDS–PAGE 
and Western blot analysis. 
(A) Coomassie brilliant blue 
staining; lane 1: markers; 
lane 2: rrVEGF-164 under 
non-reducing conditions 
(about 48 kDa); lane 3: 
rrVEGF-164 under reducing 
conditions (about 24 kDa). (B) 
Western blot analysis of the 
produced rrVEGF-164; lane 1: 
markers; lane 2: rrVEGF-164 
under non-reducing condi-
tions (about 48 kDa); lane 3: 
rrVEGF-164 under reducing 
conditions (about 24 kDa). 
(A) and (B) are both com-
posite images of VEGF-164 
monomer and dimer prod-
ucts, taken from separate 
reducing and non-reducing 
gels, respectively.
Fig. 7. Biological activity of the produced 
rrVEGF-164 and commercially available 
rrVEGF-164 analysed using a WST-1 assay. 
(A) Proliferation after 1 day of culture. (B) 
Proliferation after 3 days of culture. The 
proliferation without added VEGF was set 
to 100%. Results are means ± SD for three 
separate experiments. All values were 
significantly increased compared to the 
control values. * indicates p < 0.05 when 






mouse myeloma cell lines and E. coli have been used to produce rrVEGF- 164 commercially. The 
myeloma	and	E.	coli	production	methods	can	result	in	heterogeneity	of	molecules	with	variable	
biological	 activities28.	 Additionally,	 for	 E.	 coli	 the	 expressed	 product	 is	 present	 in	 inclusion	
bodies	 and	 in	 order	 to	 be	 active	 the	 protein	must	 be	 refolded	 (dimerised)	 after	 purification.	









provides a useful tool for basic and applied research. 
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Tissue response of 
defined collagen-elastin scaffolds in 
young and adult rats with 

















fibres.	 In	bothSprague	Dawley	and	Wistar	adult	 rats,	however,	none	of	 the	scaffolds	calcified.	
Mononuclear	cell	 infiltration	was	prominent	 in	young	and	adult	Sprague	Dawley	rats.	 In	adult	
Wistar	rats,	this	infiltration	was	associated	with	the	presence	of	microfibrils.	Degradation	of	scaffolds	
and	new	matrix	formation	were	related	with	cellular	influx	and	degree	of	vascularisation.








Tissue	 engineering	 involves	 the	 development	 of	 innovative	 biomaterials	 to	 replace	 or	 repair	
damaged	 and	 defective	 tissue.	 Type	 I	 collagen	 and	 elastin	 are	 structural	 extracellular	matrix	 
proteins	that	are	abundantly	present	in	human	tissues	and	form	natural	scaffolds	in	the	body.	
Collagen	provides	tensile	strength	and	is	widely	used	as	a	biomaterial,	e.g.	in	skin	substitutes,	
vascular	 grafts,	 scaffolds	 for	 cartilage	 repair,	 and	 bone	 implants1–3.	 Elastin	 provides	 elasticity	
to	tissues.	This,	together	with	its	stability	due	to	specific	interchain	crosslinks,	makes	elastin	a	 
desirable	protein	 for	tissue	engineering4.	 Recently,	 it	 has	been	demonstrated	 that	 the	elastin	
is	capable	of	regulating	proliferation,	migration	and	differentiation	of	vascular	smooth	muscle	
cells,	and	that	it	reduces	the	vascular	proliferative	response	to	arterial	injury	in	vivo5. This makes 





to its many calcium-binding EGF domains11.	In	dystrophic	calcinosis	cutis,	mineralisation	of	the	
elastic	fibre	has	been	shown	to	start	at	microfibrils	present	within	and	surrounding	the	elastic	 
fibre12.	In	general,	calcification	is	a	major,	not	well-understood	problem	in	biomaterial	application.	 
Especially	 cardiovascular	prosthetic	 implants	 such	as	bioprosthetic	heart	valves,	aortic	homo-
grafts	and	trileaflet	polymeric	valve	prostheses	are	prone	to	calcify.	Crosslinked	cellular	debris,	
collagen	 and	 elastin	 have	 been	 suggested	 as	 the	 onsets	 for	 calcification13–15. We previously 
described	the	preparation	and	biochemical,	biomechanical,	 immunohistochemical	and	in	vitro	
evaluation	 of	 collagen–	 elastin–glycosaminoglycan	 scaffolds16.	 In	 this	 study,	 we	 investigated	
whether	purification	of	elastin,	 i.e.	 removal	of	microfibrils,	can	(partially)	prevent	calcification	
and	may	influence	the	tissue	response	such	as	cellular	events	and	matrix	remodelling.	For	this	












Four	 different	 biomaterials	were	 prepared:	 (1)	 purified	 type	 I	 collagen,	 (2)	 purified	 insoluble	
elastin,	(3)	partly	purified	insoluble	elastin,	still	containing	microfibrils	and	some	collagen,	and	
(4)	pulverised	ligamentum	nuchae,	the	source	for	elastin.	Insoluble	type	I	collagen	was	purified	
from	bovine	achilles	 tendon	using	diluted	acetic	acid,	NaCl,	 urea,	 and	acetone	extractions	as	
described17.	 Insoluble	 elastin	was	 isolated	 from	equine	 ligamentum	nuchae	 using	 extractions	
with NaCl, organic solvents, CNBr in formic acid, urea withdiluted 2-mercaptoethanol, and diges-




anti-bovine	 elastin	 IgG	 (clone	 BA-4)	 was	 purchased	 from	 Sigma	 Chemical	 Co.	 (St	 Louis,	MO,	
USA).	Rabbit	anti-bovine	type	I	collagen,	rabbit	antirat	type	I	collagen,	and	rabbit	anti-rat	type	III	 
collagen	 IgGs	 were	 from	 Chemicon	 (Temecula,	 CA,	 USA).	 Goat	 anti-human	 type	 IV	 collagen	
IgG	 was	 from	 Southern	 Biotechnology	 Inc.	 (Birmingham,	 AL,	 USA).	 Alexa	 488-	 labelled	 goat	 
anti-mouse	IgG,	Alexa	488-labelled	goat	anti-rabbit	IgG,	and	Alexa	488-labelled	donkey	antigoat	
IgG were from Molecular Probes Europe (Leiden, The Netherlands).
Preparation of scaffolds
Four	 different	 scaffolds	 were	 prepared	 composed	 of	 purified	 collagen	 (COL),	 purified	
collagen+purified	 elastin	 in	 a	 1:1	 ratio	 (COL-EL),	 purified	 collagen+microfibril-containing	 elas-
tin	 in	 a	 1:1	 ratio	 (COL-mfEL),	 and	 purified	 collagen+pulverised	 elastic	 ligament	 in	 a	 1:1	 ratio	 
(COL–Ligament).	 Collagen	 was	 incorporated	 into	 all	 scaffolds,	 because	 we	 were	 unable	 to	 
prepare	coherent	scaffolds	of	elastin	only.	Scaffolds	were	prepared	by	lyophilising	an	acidic	1%	
suspension	of	the	various	preparations.	All	scaffolds	were	chemically	crosslinked	for	4h	with	33	
mm	 1-ethyl-3-(3-dimethyl	 aminopropyl)carbodiimide	 (EDC)	 and	 6mm	 N-hydroxysuccinimide	
(NHS) in 50mm 2-morpholinoethane sulphonic acid (MES) (pH 5.5) in the presence of 40% (v/v) 
ethanol.	After	reaction,	the	scaffolds	were	washed	in	0.1	m	Na2HPO4	(pH	9.1),	1	m	NaCl,	2	m	
NaCl, and demineralised water16,17.















ethanols	and	embedded	 in	Epon	812.	Ultrathin	sections	 (60	nm)	were	picked	up	on	 formvar-
coated	grids,	post	 stained	with	 lead	citrate	and	uranyl	acetate,	and	examined	 in	a	 JEOL	1010	
electron microscope.








observed.	 The	 study	was	 approved	 by	 the	 Ethical	 Committee	 of	 the	University	 of	 Nijmegen.	




7.2)	 (8x30	min)	at	22°C.	Rats	were	anaesthetised	with	 isoflurane.	After	disinfection,	 subcuta-
neous	pockets	were	made	to	the	right	and	 left	of	two	midline	 incisions	on	the	back.	Punches	 
(≈6	mm)	of	the	scaffolds	were	implanted	in	the	pockets	at	a	distance	of	about	1	cm	from	the	 
incisions	(4	implants/rat).	For	each	implantation	time,	two	rats	received	two	punches	of	the	same	







7.2)	 Immediately	A.	Explantation	scaffolds	 for	at	 least	24	hat	4°C,	and	embedded	 in	paraffin.	
Consecutive	sections	of	5	mm	were	mounted	onto	glass	slides,	dewaxed	in	xylol	and	hydrated	
through	a	graded	series	of	ethanol.	Sections	were	routinely	haematoxylin–eosin	stained.	Elastin	
and	 collagen	were	 stained	according	 to	Elastin	Van	Gieson	 (EVG),	 and	 calcium	deposits	were	









Immunofluorescence	microscopy	was	 used	 to	 study	 the	 biodegradation	 of	 scaffold	 collagen	 and	
elastin,	and	 the	 formation	of	new	collagens	by	 the	host.	Scaffolds	were	 frozen	 in	 liquid	nitrogen.	
Cryosections	 were	 mounted	 onto	 glass	 slides.	 After	 blocking	 with	 1%	 (w/v)	 bovine	 serum	 
albumin	(BSA)	in	PBS,	sections	were	incubated	with	mouse	anti-bovine	elastin	(1:1000),	rabbit	




















Fig. 1. (A) SDS-PAGE gel of highly purified elastin (EL; 0.5 mg), microfibril-containing elastin (mfEL; 0.5 mg) and 
pulverised ligament (0.1 mg). Only soluble contaminants and/or elastin breakdown products will enter the gel; 
insoluble elastin, which represents the vast majority of the preparations, does not. (B–D) Transmission electron 
micrographs of highly purified elastin (B), partly purified microfibril-containing elastin (C), and pulverised elastic 












of	 EDC/NHS	 crosslinking.	 In	 all	 scaffolds,	 35–40%	of	 amine	 groups	were	 used	 in	 crosslinking.	 
Collagen	possesses	a	larger	amount	of	amine	groups	than	elastin,	which	explains	the	absolute	
values	for	the	different	preparations	(Table	1).
Fig. 2. Scanning electron micrographs of the crosslinked scaffolds. (A) COL, (B) COL-EL, (C), COL-mfEL, and (D) COL-liga-
ment. Collagen is present as thin fibrils and sheets, elastin as thick fibres. Arrows indicate elastic fibres. Bar is 10 mm.
Table 1; Amine group content of various scaffolds
COL: scaffold composed of colla-
gen only; COL-EL: scaffold com-
posed of equal amounts of col-
lagen and highly purified elastin;
COL-mfEL: scaffold composed of 
equal amounts of collagen and 
microfibril-containing elastin; 
COL-ligament: scaffold com-
posed of equal amounts of colla-
gen and pulverised ligamentum 
















and	 COL-ligament	 had	 increased	 (Fig.	 3).	 COL-EL	 and	 COL-mfEL	 calcified	 to	 about	 the	 same	 
extent.	In	COLligament,	calcification	had	extended	to	collagen.
Adult	Sprague	Dawley	rats	and	Adult	Wistar	 rats:	All	 scaffolds	 implanted	 in	adult	 rats	did	not	
show	any	calcification	up	to	day	21.	
Fig. 3. Light microscopical evaluation of the calcification of scaffolds, 21 days after implantation in young Sprague 
Dawley rats. (A) COL, (B) COLEL, (C), COL-mfEL, and (D) COL-ligament. Calcium deposits have an intense black colour 







Tissue response to scaffolds
Figs.	4	and	5	show	some	representative	examples	of	the	tissue	response	to	scaffolds	in	young	and	
adult	Sprague	Dawley	rats	and	adult	Wistar	rats	at	different	time	points	(see	Table	2).	
Table 2; General overview of 
calcification and cellular events 
after subcutaneous implanta-









b  Blood vessels were assessed by immunostaining for rat type IV collagen, present in vascular basement mem-
branes.
c		One	out	of	four	implanted	collagen	scaffolds	showed	moderate	calcification	at	this	time	point.
Young Sprague Dawley rats
At day 3, several macrophages and some polymorphic nuclear granulocytes (PMNs) were present, 
mostly	at	the	periphery	of	the	scaffold.	More	PMNs	were	present	near	elastic	ﬁbres than near 





cells	 and	mast	 cells.	 Foreign	 body	 giant	 cells	 (fused	macrophages	with	multiple	 nuclei)	were	
encountered in variable amount. At day 21, capillaries were present in between the ﬁbres of the 






Fig. 4. Light microscopical overview of the cellular response to scaffolds at day 21 in young Sprague Dawley rats. 
(A) COL, (B) COL-EL, (C), COLmfEL, and (D) COL-ligament. Note the increased amount of mononuclear cell infiltra-
tion, especially in COL-Ligament scaffolds. Sections were HE stained. C=capsule; G=giant cell; arrows indicate elastic 
fibres. Bar is 50 mm.
Adult Sprague Dawley rats
At	 day	 3,	 all	 implants	were	 encapsulated	with	 a	 fibrous	 capsule.	 Some	 PMNs	 had	 infiltrated	
mainly	COL-mfEL	and	COL-ligament	(Fig.	5A	and	B),	while	more	phagocytic	cells	infiltrated	COL	
and	COL-EL.	At	day	7,	PMNs	were	only	sporadically	found.	Increased	fibrous	encapsulation	was	












Fig. 5. Light microscopical evaluation of the cellular response to scaffolds implanted in adult Sprague Dawley rats 
(A–D) and adult Wistar rats (E–F). (A) COL-EL and (B) COL-mfEL 3 days after implantation. Note that more PMN’s 
(neutrophiles) are present in COL-mfEL than in COLEL. (C) COL-EL and (D) COL 7 days after implantation. In COL, an 
increase of mononuclear cells, especially non-phagocytic cells, was found at the periphery of the scaffold. (E) COL-
EL and (F) COL-mfEL 21 days after implantation. In COL-mfEL, locally an increase of mononuclear cells was found. 
Sections were HE stained. C=capsule; G=giant cell; arrow heads indicate neutrophiles; arrows indicate elastic fibres. 










Vascularisation of the scaffolds
Young	Sprague	Dawley	rats:	Few	small	blood	vessels,	visualised	by	immunostaining	for	type	IV	









Fig. 6. Immunostaining of COL-EL scaffolds for types IV and III collagen as indicators of vascularisation and matrix 
production after subcutaneous implantation in adult Sprague Dawley rats. (A) COL-EL after 7 and (B) after 21 days 
immunostained for type IV collagen. At day 7, type IV collagen staining is mainly present at the periphery, at day 
21 in the whole scaffold. (C) COL-EL after 7 days and (D) after 21 days immunostained for type III collagen. At day 
7, type III collagen staining is mainly present at the scaffold periphery, at day 21 it is found throughout the scaffold. 







Scaffold degradation and new matrix synthesis
Table	3	gives	an	overview	of	the	immunofluorescence	staining	for	scaffold	components	and	for	
newly	formed	extracellular	matrix	molecules	at	different	time	points.
Table 3; Overview of immunostaining results of explants for scaffold and rat extracellular matrix components
COL: crosslinked collagen scaffold; COL-EL: crosslinked scaffold composed of equal amounts of collagen and highly 
purified elastin; COL-mfEL: crosslinked scaffold composed of equal amounts of collagen and microfibril-containing 
elastin; COL-ligament: crosslinked scaffold composed of equal amounts of collagen and pulverised ligamentum 
nuchae.
Events were scored ranging from sporadic (sp) to abundant (++). -: not present.
Scaffold degradation
Young	Sprague	Dawley	rats:	Conventional	histology	showed	small	amounts	of	degraded	collagen	
which were locally visible from day 7 on at the periphery. At day 21, degraded collagen was also 
found	deeper	within	the	scaffolds,	but	especially	centrally	a	large	amount	of	intact	scaffold	col-
lagen	remained	present.	 Immunostaining	 for	bovine	type	 I	collagen	supported	these	findings.	












Adult Sprague Dawley rats: Degraded collagen was visible at the periphery at day 7. Fragmented 
elastin	(bothEL	and	mfEL)	was	visible	locally	from	day	7	on.	Especially	in	COL-ligament	scaffolds,	







capsule	 surrounding	 the	 implant	 and	 aligning	with	 the	 collagen	 fibrils	 in	 the	 scaffold.	 At	 day	





Dawley rats: In adult Sprague Dawley rats, staining for rat type I and III collagen was similar to 








































solutions	to	prevent	calcification	are	aluminium	chloride	treatment9, ethanol/ EDTA treatment28, 
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A Biomaterial Composed of Collagen 
and Solubilized Elastin Enhances 

























lagenous	part	of	 the	scaffolds	and	 that	persisted	after	chemical	 cross-linking	of	 the	scaffolds.	
Crosslinked	scaffolds	were	subcutaneously	 implanted	in	young	Sprague	Dawley	rats.	Collagen-












Elastin	 is	 the	major	 insoluble	protein	present	 in	elastic	tissue,	contributing	to	the	elasticity	of	













types.	We	have	previously	prepared	biomaterials	 composed	of	highly	purified	 type	 I	 collagen	
and	elastin	fibers	and	studied	their	tissue	reaction.13, 14  In young Sprague Dawley rats (but not 
in	adult	rats),	implantation	of	these	scaffolds	resulted	in	calcification	of	elastin	fibers.	Although	
initiation	of	tissue	calcification	does	not	require	a	cellular	response,15 the in vivo milieu can accel-
erate the process16	(e.g.,	through	the	extracellular	release	of	enzymes	by	macrophages	and	giant	
cells	involved	in	elastin	degradation).17-20	We	here	hypothesize	that	porous	scaffolds	containing	




















anti-bovine	type	 I	collagen,	 rabbit	anti-rat	 type	 I	collagen,	and	rabbit	anti-rat	 type	 III	collagen	
IgGs	from	Chemicon	(Temecula,	CA);	and	goat	anti-human	type	IV	collagen	IgG	from	Southern	
Biotechnology	 Inc.	 (Birmingham,	AL).	Rabbit	anti-human	fibrillin-1	(pAb-rF6H)	and	rabbit	anti- 
human	fibrillin-2	(anti-rFBN2-1)	anti-sera	were	prepared	as	described	previously.22, 23	Alexa488-	
and	Alexa594-labeled	secondary	antibodies	were	 from	Molecular	Probes	Europe	 (Leiden,	The	
Netherlands),	 and	 rabbit	 anti-goat	 peroxidase	 and	 3,3-di-aminobenzidine	 tetrahydrochloride	
(DAB)	were	from	DAKO	(Glostrup,	Denmark).
Isolation of scaffolds components
Insoluble	type	I	collagen	was	purified	from	bovine	Achilles	tendon.	Briefly,	tendons	were	cleaned	
from	noncollagenous	tissue,	pulverized	under	liquid	nitrogen	conditions	using	a	Pulverisette	19	
with	 a	 0.5-mm	 sieve	 (Fritsch,	 Idar-Oberstein,	Germany),	 and	 consecutively	 rinsed	 extensively	
with 0.1M sodium chloride (NaCl) in 50mM Tris-hydrochloric acid (HCl) pH 7.2, 1.0M NaCl in 
50mM	Tris-HCl	pH	7.2,	4M	urea	in	0.5M	acetic	acid,	0.5M	acetic	acid,	acetone,	and	demineralized	
water.24	 Insoluble	elastin	fibers	 (ELfiber)	were	 isolated	from	equine	 ligamentum	nuchae.	Non-
elastinous	tissue	was	removed,	and	ligaments	were	pulverized	under	liquid	nitrogen	conditions	
through a 1.0mm sieve. The pulverized ligament was then washed and treated with 1M NaCl in 
10mM	phosphate	buffer	pH	7.4	(PB),	various	organic	solvents,	formic	acid	with	cyanogen	trypsin	
bromide, 4M urea plus 1M 2-mercaptoethanol in 0.1M PB, trypsin, and 1M NaCl in 10mM PB.25 
Solubilized	elastin	(ELsol)	was	prepared	from	insoluble	elastin	fibers	using	oxalic	acid	hydroly-







was determined according to the method develop by Lowry,27	size	of	elastin	using	1-dimensional	
gel electrophoresis (4% polyacrylamide gel with silver staining),28	and	gel	permeation	chromatog-
raphy29	[column	material:	Sephacryl	S-500,	reference	samples:	ferritin	(0.88MDa),	dextran	blue	
(2MDa),	and	Helix	pomatia	hemocyanin	(9	MDa)],	size-charge	distribution	using	2-dimensional	
gel electrophoresis,30	 amine	 group	 content	 after	 reaction	 with	 2,4,6-trinitrobenzene	 sulfonic	
acid,31	and	amino	acid	composition	using	a	Biochrom	20	amino	acid	analyser	(Amersham	Phar-








shaken	overnight	in	0.5M	acetic	acid	at	4oC. If appropriate, ELsol was added and the suspension
diluted	to	1%	(w/v)	with	cold	MilliQ	water	and	homogenized	on	ice	using	a	Potter-Elvehjem	homog-










and lyophilized.13, 33	For	 in	vivo	experiments,	EDC/NHS-crosslinked	COL	and	COL-ELfiber	1:1	scaf-
folds	from	a	1.0%	suspension	were	used	along	with	COL-ELsol	1:1	scaffolds	from	a	1.6%	suspension.
Characterization of scaffolds
The amine group content was measured to evaluate the degree of crosslinking.31 The amount of 
Elsol	bound	to	collagen	was	established	by	estimating	the	protein	content	in	the	solution	after	
crosslinking.	Proteins	 in	 this	solution	were	precipitated	with	10%	2,4,6-trichloroanisole	on	 ice	
for	2	h	and	centrifuged.	The	pellet	was	then	dissolved	in	10mM	sodium	hydroxide	and	the	pro-





ning	electron	microscopy	was	used	to	analyze	the	morphology	of	the	scaffolds,13   transmission 
electron	microscopy	to	determine	the	ultrastructure	of	the	scaffolds,25	and	immunofluorescence
microscopy	 to	 study	 the	distribution	of	ELsol	 in	 the	scaffolds	using	mouse	anti-bovine	elastin	
(1:1000)	as	a	primary	antibody.14
In vivo evaluation of scaffolds
The	Ethics	Committee	of	the	Radboud	University	Nijmegen	Medical	Centre	approved	the	study.	
























At	 least	 two	persons	performed	histological	evaluation	 independently.	 Immunohistochemistry	
(immunofluorescence	and	DAB	staining)	was	used	to	study	the	biodegradation	of	scaffold	com-
ponents	and	the	 formation	of	extracellular	matrix	by	the	host.	Scaffolds	were	 frozen	 in	 liquid	
nitrogen,	and	5-mm	cryosections	were	mounted	on	superfrost	slides	and	air	dried.	Immunofluo-







with rat type I collagen or vice versa. 
For	 immunohistochemistry	 with	 the	 DAB-staining	 method,	 cryosections	 were	 fixed	 with	 4%	
paraformaldehyde	in	PBS	for	20	min.	Endogenous	peroxidase	was	inhibited	with	0.3%	hydrogen	





















± standard	deviation	of	the	solubilized	elastin	was	292± 5 nmol amine groups per mg of protein. 
Amino	acid	composition	of	solubilized	elastin	was	similar	to	that	of	elastin	fibers	for	all	amino	
acid residues, including desmosine and isodesmosine (both 0.5± 0.0 per 1000 amino acid
residues).





























Tissue response to implanted scaffolds 
All	animals	remained	in	good	condition,	and	no	infections	were	observed.	Macroscopically,	a	thin	
capsule	was	 	 seen	around	 the	 scaffolds	at	explantation.	 In	Table	2,	an	overview	of	 calcification	
behavior and cellular response is given 
for	 the	3	different	 scaffolds.	 Tissue	 re-
sponse	to	COL	and	COL-ELfiber	scaffolds	
was consistent with previous results.14
Fig 1. Morphology of scaffolds as analysed 
by scanning electron microscopy. (A, B) 
non-crosslinked (NX) COL-ELsol; (C, D) EDC/
NHS-crosslinked (X) COL-ELsol; (E) COL and (F) 
COL-EL
fiber 
scaffolds. A and C represent cross-
sectional views, whereas B , D, E and F are en-
larged to views. Arrowheads indicate insoluble 
elastin fibres en COL-EL
fiber
, whereas arrows 
indicate spherical structures that are only 
present in the COL-ELsol. Spherical structures in 
EDC/NHS-crosslinked COL-ELsol are somewhat 
deformed compared to non-crosslinked COL-
ELsol (inserts in B and D). Bar is 100 µm in A 





Fig.2 Microscopical evaluation 
of spherical structures in collagen 
with solubilized elastin (COL-ELsol) 
scaffolds. (A) Immunofluorescence 
staining for elastin and (B) auto-
fluorescence visualization using ul-
traviolet optics in 1-ethyl-3-(3-de-
methylaminopropyl)carbodiimide/ 
6 mM N-hydrocysuccinimide (EDC/
NHS)-crosslinked scaffolds show 
hat spherical structures are com-
posed of ELsol. (C, D) Transmis-
sion electron microscopy images 
display that ELsol spheres (White 
arrowheads) are incorporated in 
the collagenous structures (white 
arrows) of EDC/NHS crosslinked 
scaffolds. Bar is 50 µm in A, B and 




7 on. At day 7, 3.5% ±	0.1%	of	the	total	scaffold	surface	had	calcified,	whereas	at	day	21,	it	was	
11.5%± 0.7%,	which	was	statistically	significant	(	p<0.05).
Fig. 3 Light microscopy evaluation of calcification of scaffolds 21 days after implantation in young Sprague-Dawley 
rats. (A) Collagen Alone (COL), (B) collagen plus insoluble elastin fibre (COL-EL
fiber
), (C) collagen with solubilised 
elastin (COL-ELsol) scaffolds. Calcium deposits have an intense black colour due to Von Kossa staining and are only 
found in COL-EL
fiber


































Fig. 4 Light microscopical 
evaluation of angiogen-
esis in scaffolds 21 days 
after implantation in young 
Sprague-Dawley rats. Sec-
tions were stained for type 
IV collagen as a marker for 
blood vessels. (A) Collagen 
alone (COL), (B) collagen 
plus insoluble elastin fibre 
(COL-EL
fiber
), (C) periphery 
of collagen with solubilised 
elastin (COL-ELsol), (D) with-
in COL-ELsol scaffold. Bar is 
50 µm. (E) Quantification 
of blood vessels in the scaf-
fold using type IV collagen 
and expressed as a per-
centage of the total area. 
At day 21, COL-ELsol had 
significantly more blood 




Scaffold degradation and new matrix synthesis











and	after	21	days,	elastin	 staining	was	 reduced	even	more.	Elastin	 spheres	were	 still	 present	
at	this	time,	especially	 in	the	central	part	of	the	scaffolds	(Fig.	5A,	B).	At	the	periphery	of	the	 





on. At day 21, degraded collagen was also found more centrally, whereas only minor amounts of 
fragmented	collagen	were	found	in	COL.	Elastin	and	collagen	degradation	in	COL-ELfiber	and	COL	
was consistent with that found in previous studies.14
Fig. 5. Elastin Van Gieson-stained paraffin sections of collagen with solubilised elastin (COL-ELsol) scaffolds shows 
that Elsol Spheres from the scaffold are still present 21 days after implanting in Young Sprague-Dawley rats. Within 
the scaffolds, elastin spheres (arrows) are still quite large (A), but at the periphery of the scaffolds, the elastin 
spheres are smaller (B). Elastin Von Gieson stains elastin black and collagen pink or red. Bars represent 20 µm. (C) 
Semi-thin epon sections of crosslinked COL-ELsol scaffolds that were implanted for 7 days in young Sprague-Dawley 
rats stained with toluidine blue and basic fuchsin. Flattened cells aligned with the scaffold lamellar structure and 
were accompanied by extracellular matrix formation. Cells stain Blue, new extracellular matrix stains light pink and 
























staining (Fig. 6C, F).
Fig. 6 Fluorescence microscopy evaluation of newly formed elastic fibres in scaffolds, 21 days after implantation in 
young Sprague-Dawley rats. Sections were stained for rat elastin (A-C, G-I), fibrillin-1 (D-F) and fibrillin-2 (J-L). Espe-
cially in collagen with solubilised elastin (COL-ELsol) scaffolds, threadlike structures (arrows) positive for rat elastin 
and fibrillin-1 were observed. Blood vessels mainly colocalized with fibrillin-2 and to a lesser extend with fibrillin-1. 
Insert in F shows an example of colocalized rat elastin and fibrillin-1 in blood vessels; insert in L shows that thin rat 













dent on the animal model used. In a previous study, we showed that (young and adult) Sprague- 
Dawley	 rats	 showed	more	tissue	 reaction	 to	 subcutaneously	 implanted	 scaffolds	 than	 (adult)	
Wistar rats.14	As	a	consequence,	more	vascularization	and	collagen	production	was	observed	in	

















































collagen–elastin	films	stabilized	using	glutaraldehyde	fixation,36 but this treatment increases cal-
cification	of	biomaterials.47	In	a	cranial	lesion	in	adult	rats,	a	polypentapeptide	based	on	elastin	
with	an	amino	acid	sequence	of	(Val-Pro-Gly-Val-Gly)n	was	also	able	to	 initiate	calcification	in	
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An	 important	 issue	 in	 tissue	 engineering	 is	 the	 vascularisation	 of	 the	 implanted	 construct,	





prepared and characterised viz.: collagen, collagen with heparin, and collagen with heparin plus 
one	or	two	growth	factors	(rrFGF2	and	rrVEGF).	Scaffolds	were	subcutaneously	implanted	in	3	
months	old	Wistar	 rats.	Of	all	 scaffolds	 tested,	 the	one	with	a	combination	of	growth	 factors	
displayed the highest density of blood vessels (type IV collagen) and most mature blood vessels 
(smooth	muscle	actin).	In	addition,	no	hypoxic	cells	were	found	in	this	scaffold	at	day	7	and	21	
(hypoxia	inducible	factor	1-α).	These	results	indicate	that	the	addition	of	both	FGF2	and	VEGF	to	














mum	diameter	for	cellular	adhesion	and	migration	(~100	µm)6. Furthermore, endothelial cells 
and	fibroblasts	have	been	included	in	gelatine-coated	polystyrene	scaffolds	in	order	to	initiate	
angiogenesis in vitro,	resulting	in	sprouts	prior	to	transplantation7.	The	addition	of	glycosamino-
glycans and growth factors also proved to increase angiogenesis in vivo1.	However,	it	still	takes	
about	four	weeks	to	develop	sufficient	vasculature.	
Angiogenesis	 is	a	multifactor	process,	which	 is	regulated	by	an	 interplay	of	a	 large	number	of	 
factors.	Angiogenesis	can	be	set	on	by	e.g.	hypoxia8.	An	important	stimulating	factor	in	angio-
genesis is vascular endothelial growth factor (VEGF) which acts on the VEGF receptors (VEGFR). 
VEGF	stimulates	cells	to	produce	matrix	metalloproteinases	(MMPs)	that	degrade	the	basement	
membrane	and	 surrounding	extracellular	matrix.	As	 a	 result,	 endothelial	 cells	 proliferate	 and	
migrate	towards	the	interstitium,	where	they	start	sprouting.	Subsequently,	pericytes	prolifer-
ate	and	migrate	towards	the	newly	formed	sprouts	and	induce	maturation	by	forming	a	single	
cell layer around the sprout9,10.	The	administration	or	overexpression	of	single	VEGF	isoforms	in	







at least three weeks12.
Clearly,	the	administration	of	one	growth	factor	is	not	sufficient	to	create	well-developed	ma-
ture	blood	vessels.	Few	authors	have	studied	the	combined	administration	of	growth	factors.	
Tumour cells, transfected with VEGF and/or FGF2, need both VEGF and FGF2 to form blood ves-
sels13.	Similar	synergistic	effects	were	found	by	local	administration	of	VEGF	and	FGF2	in	a	rabbit	
ischemic	hind	limb	resulting	in	a	higher	capillary	density	and	capillary	vs.	muscle	fibre	ratio	than	
either VEGF or FGF2 alone14. 
In	this	study,	we	tested	the	hypothesis	that	the	combined	application	of	recombinant	rat	VEGF-
164 (rrVEGF) and recombinant rat FGF2 (rrFGF2) increases angiogenesis in acellular collagen-
heparin	scaffolds	for	tissue	engineering.	For	that	purpose,	scaffolds	consisting	of	combinations	








2 Materials and methods
2.1  Materials
Unless stated otherwise all chemicals were purchased from Merck Chemicals (Darmstadt, 
Germany).	Type	I	collagen	was	purified	from	bovine	achilles	tendon	using	diluted	acetic	acid,	
NaCl,	 urea	 and	 acetone	 extractions15. Heparin was purchased from Sigma Chemical Co. (St 
Louis,	MO,	USA).	Recombinant	rat	FGF2	was	produced	in	E. coli M15 PQE16 and recombinant 
rat VEGF-164 in P. pastoris GS1151. 







The	 scaffolds	 were	 prepared	 by	 freezing	 a	 0.8%	 collagen	 suspension	 in	 diluted	 acetic	 acid	
at -20°C1,16	 and	 subsequently	 lyophilising	 in	 a	 Zirbus	 lyophiliser	 (Bad	 Grund,	 Germany).	 All	
scaffolds	were	 chemically	 crosslinked	with	 and	without	 2.75%	heparin	 for	 4	 h	with	 33	mM	
1-ethyl-3-dimethyl	 aminopropyl	 carbodiimide	 (EDC)	 and	6	mM	N-hydroxysuccinimide	 (NHS)	
in	50	mM	2-morpholinoethane	sulphonic	acid	(pH	5.0)	in	the	presence	of	40%	ethanol.	After	




2.3 Characterisation of scaffolds













antibodies	 visualised	with	 a	 chemiluminescent	 detection	 kit	 (ECL)	 (Amersham	Biosciences).	
Gene Tools (Syngene, Cambridge, UK) was used to analyse the intensity of the bands. 0-100 
ng	growth	factor	was	used	as	a	standard	curve.	Scaffolds	without	growth	factors	were	taken	
as controls.
Immunofluorescence microscopy was	used	to	determine	the	distribution	of	 type	 I	collagen	 ,	
heparin,	FGF2		and	VEGF	in	the	scaffolds,	as	described20	(for	dilutions	see	Table	1).	Omission	of	
the	primary	antibody	was	taken	as	a	negative	control.
2.4 Implantation of scaffolds 
NIH	guidelines	for	the	care	and	use	of	 laboratory	animals	(NIH	publication	85-23	Rev.	1985)	
were	observed.	The	study	was	approved	by	the	Ethics	Committee	of	the	Radboud	University	
Nijmegen. Wistar rats (male, 3 months) were purchased from Harlan (Horst, The Netherlands). 
The rats were housed per 2, fed pelleted diet (RMH-B 10 mm) and water ad libitum. The rats 
were	 anaesthetized	with	 isoflurane.	 After	 disinfection,	 4	 subcutaneous	 pockets	were	made	
on	both	sides	of	 two	midline	 incisions	on	the	back.	Scaffolds	 (Æ 6 mm) were washed in 70% 
ethanol	(4x	30	min)	and	sterile	PBS	(8x	30	min)	and	placed	in	the	pockets	at	about	1	cm	of	the	
incision.	Each	rat	received	4	implants	(2	different	scaffolds).	At	day	3,	7	and	21,	the	implants	
with	 surrounding	 tissue	were	 removed.	 The	 explants	were	 divided	 in	 halves;	 one	 half	 was	
processed	for	conventional	histology	and	the	other	for	immunohistochemistry.
2.5 Processing of explants
Conventional histology:	 to	 study	 the	 cellular	 reaction,	 paraffin	 sections	 were	 cut	 and	
haematoxylin-eosin	 stained21.	 Histology	 of	 the	 scaffolds	was	 evaluated	 independently	 by	 at	
least	two	experienced	investigators.
Immunostaining:	To	study	formation,	maturation	and	functionality	of	blood	vessels,	sections	
were	 stained	 with	 specific	 antibodies.	 Type	 IV	 collagen	 (COL	 IV)	 was	 used	 to	 manually	
















Peroxidase-antiperoxidase method, the	 peroxidase-antiperoxidase	 method	 was	 used	 to	
immunolocalise	molecules	(hypoxia	inducible	factor	1-α	and	smooth	muscle	actin)	in	paraffin	
sections.	5	µm	sections	were	deparaffinised	and	 incubated	as	described21	 (for	dilutions	 see	
Table 1).
Figure 1. Microscopical evaluation 
of the different scaffolds. Scanning 
electron micrograph of a cross-
section of COL (A) and COLH scaf-
fold (B). Immunolocalisation of type 
I collagen (C), heparin (D), FGF2 (E) 
and VEGF (F) in a COLHFV scaffold. 

















The	 distribution	 of	 the	 different	 components	 in	 the	 scaffolds	 was	 visualised	 using	
immunofluorescence	 and	 revealed	 that	 heparin,	 FGF2	 and	 VEGF	 were	 equally	 distributed	
throughout	the	scaffold	(Fig.	1C-G).	
Figure 2. Quantification of VEGF and 
FGF2 bound to collagen-heparin 
scaffolds using Western blotting.
A) Detection of VEGF and FGF2 in 
various collagen-heparin scaffolds.
B) Standard curve of VEGF after 
band analysis (0-100 ng).
COLHV= collagen-heparin-VEGF 
scaffold; COLHFV= collagen-heparin-












at	 the	outer	part	of	 the	 scaffold,	whereas	COLHF	and	COLHV	showed	a	moderate	amount	of	
macrophages,	 fibroblasts	 and	 some	 granulocytes	 further	 in	 the	 scaffold.	 COLHFV	 showed	 a	
moderate	amount	of	granulocytes,	macrophages	and	some	fibroblasts	throughout	the	scaffold	
(Fig. 3). A thin layer of capsule surrounded all implants.
At	day	7,	no	granulocytes	were	present	in	the	scaffolds	anymore.	Few	giant	cells	were	found	at	this	
time	point.	The	cellular	response	to	COL	and	COLH	included	a	moderate	amount	of	macrophages	
and	 some	fibroblasts	 further	 in	 the	 scaffold.	 COLHF	 and	COLHV	 showed	a	moderate	 amount	




At	 day	 21,	 macrophages	 and	 non-phagocytic	 cells	 were	 present	 throughout	 COL	 and	 COLH	
scaffolds.	A	larger	amount	of	macrophages,	giant	cells,	fibroblasts	and	non-phagocytic	cells	was	
found	 throughout	 the	COLHF,	COLHV	and	COLHFV	 scaffolds.	All	 scaffolds	 contained	a	 capsule	
















COL	 IV	 staining)	 (Fig.	 4	and	5).	 	COLHFV	 showed	most	 SMA-positive	blood	vessels	 (35%	±	4),	
more	than	COLHF	(18.3%	±	7.4),	COLH	(17.2%	±	0.9)	and	COLHV	(16.9%	±	2.2).	No	significant	
differences	were	found	between	COLHV-COLHF,	COLHV-COLH	and	COLHF-COLH.
Figure 3. Histological evaluation of scaffolds explanted at day 3. 
Haematoxylin-eosin staining of  COL (A), COLH (B), COLHF (C), COLHV (D) 
and COLHFV (E). COL and COLH only showed some cells in the outer part of 
the scaffold, whereas the scaffolds with growth factors (COLHF, COLHV and 







Figure 4. Macroscopical (A) 
and immunohistochemical 
evaluation of the scaffolds 
explanted at day 7 (B, C).
A)  Macroscopical evaluation 
of a non-implanted scaf-
fold at day 0 and explants 
at day 7 (COL, COLHV and 
COLHFV). Note the red ap-
pearance of the COLHFV 
scaffold.
B)  Immunohistochemical evaluation using type IV collagen staining of the scaffolds explanted at day 7. COLHFV 
showed the most and largest area of blood vessels compared to COLHV, COLHF and COLH. No blood vessels were 
found in COL at this time point. 
C)  Immunohistochemical evaluation using smooth muscle actin staining of scaffolds explanted at day 7. COLHFV 
displayed the largest percentage of mature blood vessels compared to COLHV, COLHF and COLH. Arrows indicate 
SMA-positive blood vessels. Bar is 50 µm.
Figure 5. Analysis of the blood vessels present in the scaffolds using COL IV and SMA staining. Scaffolds containing 
two growth factors showed both a larger total area of blood vessels and more mature blood vessels.
A)  The total area of blood vessels per scaffold was calculated from COL IV staining.  At day 7, COLHFV had significantly 
more blood vessel area than all the other scaffolds.  At day 21, COLHV had a significantly larger blood vessel area 
than all the other scaffolds with the exception of COLHV. * p<0.05.
B)  The total area of mature blood vessels (staining positive for SMA) was expressed as a percentage of the total area 
of blood vessels. At day 7 and at day 21, COLHFV had a significantly higher percentage of SMA positive blood 






COLHFV	more	 than	COLH	 and	COLHF	 (3.2%	±	 0.9),	 but	 no	 significant	 differences	were	 found	
between	COLHFV-COLHV,	COLHV-COLHF,	COLHV-COLH,	COLHF-COLH	and	COLHF-COL.	
COLHFV	(83.4%	±	4.9)	showed	a	significant	higher	percentage	of	SMA-positive	blood	vessels	than	














Figure 6. Immunohistochemical analysis of HIF1-α staining of cells in the scaffolds at day 3, 7 and 21.
A)  Photographs of COLHFV scaffold at day 3 and 7. COLHFV showed many hypoxic cells at day 3 and few at day 7. 
Inserts show that HIF1-α predominantly stains the nuclei of cells. Positive cells stain black and negative cells stain 
blue. Bar is 10 µm.
B)  Statistical analysis of the percentages of HIF1-α positive cells. At day 7 and 21, COLHFV had significantly less 








In	 tissue	 engineering,	 vascularisation	 of	 the	 transplanted	 constructs	 is	 often	 limited	 at	 early	
time	 points	 and	 this	 seriously	 hampers	 the	 survival	 of	 cells.	 Cells	 die	 due	 to	 lack	 of	 oxygen,	
nutrients	and	inadequate	removal	of	waste	products.	This	confines	the	size	of	tissue-engineered	
constructs	 to	 a	maximum	of	 a	 few	 cm2 4. Generally, it takes several weeks for a construct to 
become fully vascularised. This slow development of blood vessels hampers wound healing or 
tissue	regeneration	in	certain	pathological	conditions3,5. A means to increase angiogenesis is to 
administer	growth	factors	either	by	 injection	or	preferably	 in	a	slow-release	system	such	as	a	
bioscaffold.	Scaffolds	can	be	built	up	from	several	components	and	in	this	study,	we	used	highly	
purified	 type	 I	 collagen,	 heparin,	 recombinant	 rat	 FGF2	 and	 recombinant	 rat	 VEGF.	We	 have	
previously	shown	that	collagen-heparin	scaffolds	can	give	sustained	release	of	FGF21. Therefore, 
five	 different,	molecularly-defined,	 scaffolds	were	made,	 including	 collagen-heparin	with	 and	
without	one	or	two	growth	factors.	Porous	collagen	scaffolds	(containing	pores	of	about	100	µm)	
were	prepared	by	lyophilisation	and	heparin	was	covalently	attached	to	allow	coupling	of	one	
or two heparin-binding growth factors (FGF2 and VEGF). The amount of bound FGF2 resembled 
the amount found by Pieper et al., who used 125I-FGF2 to analyse the amount of bound growth 
factor1.	More	FGF2	than	VEGF	was	able	to	bind	to	collagen-heparin	scaffolds,	perhaps	due	to	
minor	 differences	 in	 their	 affinity	 for	 heparin25,26.	 Less	 FGF2	 and	 VEGF	 bound	 to	 the	 scaffold	





Many	 different	 factors,	 stimulators	 as	 well	 as	 inhibitors,	 are	 involved	 in	 angiogenesis,	 and	
they all have their own mechanism9. VEGF is found to be one of the most important factors 
in	 angiogenesis.	 It	 stimulates	 endothelial	 cells	 by	 binding	 to	 VEGFR-2,	 thus	 inducing	 MMP	
production,	proliferation	and	migration	of	the	endothelial	cells.	FGF2	upregulates	the	expression	
of VEGF25	and	attracts	pericytes,	which	form	a	single	cell	layer	around	the	newly	formed	capillary,	
necessary	 to	 mature	 the	 blood	 vessel	 and	 to	 protect	 it	 from	 degradation11.	 A	 HIF1-α/FGF2	
amplification	pathway	in	which	FGF2	upregulates	HIF1-α,	leading	to	an	angiogenic	response	has	






tissue28.	 FGF2	 stimulates	 proliferation	 and	 differentiation	 of	 granulocytes,	 endothelial	 cells,	
fibroblasts	and	many	other	cells.	Granulocytes	also	produce	MMPs	that	degrade	the	extracellular	













only	 be	 suppressed	by	 complete	 inhibition	of	VEGF,	 FGF2	 and	platelet	 derived	 growth	 factor	
(PDGF). We do not need PDGF to develop mature blood vessels, perhaps because VEGF and FGF2 
are	capable	to	upregulate	the	production	of	PDGF;	a	combined	administration	of	VEGF	and	FGF2	
has	been	reported	to	be	sufficient	to	develop	mature	blood	vessels	in	the	absence	of	PDGF9. 
To	 analyse	whether	 the	 formed	 blood	 vessel	were	 functional,	we	 used	 a	marker	 for	 hypoxia	
(HIF1-α).	Under	hypoxic	conditions	HIF1-α	is	accumulated	and	transported	to	the	nucleus	where	
it	dimerizes	with	HIF1-β	to	its	active	form31. The staining revealed that the formed blood vessels 
were	 capable	 of	 supplying	 the	 infiltrated	 cells	with	 sufficient	 oxygen.	 The	 scaffold	with	 both	
FGF2	and	VEGF	showed	almost	no	hypoxic	cells	from	day	7	on.	It	usually	takes	3	to	4	weeks	for	
a construct to become fully vascularised1,12.	We	show	a	huge	reduction	in	the	time	needed	to	
induce	angiogenesis.	This	benefits	tissue	regeneration,	especially	when	you	consider	that	this	
process	requires	sufficient	blood	vessels	to	be	present32.
The	 combination	of	VEGF	and	 FGF2	 is	 capable	of	 providing	 the	 scaffold	with	 enough	mature	
blood	vessels	to	supply	the	cells	of	oxygen	and	nutrients	at	a	very	early	time	point.	Bioscaffolds	
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Design and in vivo evaluation of a 
molecularly-defined acellular skin 
construct:
reduction of early contraction and increase in 













factor 7 (FGF7), whereas the porous dermal layer was prepared using type I collagen, solubilised 
elastin,	dermatan	 sulfate,	heparin,	fibroblast	 growth	 factor	2	 (FGF2)	 and	vascular	endothelial	
growth factor (VEGF). The construct was biochemically and morphologically characterised and 
evaluated in vivo using a rat full-thickness wound model. Results were compared with the com-








to IntegraDRT and/or the untreated wound. At day 14, the double-layered skin construct also had 
the	least	myofibroblasts	present.	At	day	112,	the	double-layered	skin	construct	contained	more	
elastic	fibres	than	IntegraDRT	and	the	untreated	wound.	Structures	resembling	hair	follicles	and	
sebaceous glands were found in the double-layered skin construct and the untreated wound, but 
hardly	any	were	found	in	IntegraDRT.	The	results	provide	new	opportunities	for	the	application	of	







and	hydration,	and	acts	as	a	barrier	against	infection1. Human full-thickness defects larger than 4 
cm	in	diameter	will	not	heal	well	without	a	graft2.	Currently,	autologous	grafts	present	the	most	
effective	treatment	modality,	but	their	availability	is	limited,	and	the	harvest	of	autologous	skin	




tained FDA approval and are available for clinical use, including Apligraf and IntegraDRT2. Apligraf 
is	a	cell-based	construct	consisting	of	an	epidermal	layer	of	human	keratinocytes	and	a	dermal	
layer	composed	of	bovine	type	I	collagen	and	human	fibroblasts5. This construct is known to be a 
safe	and	effective	graft	for	use	in	chronic	wounds.	The	cellularity	of	constructs,	however,	makes	it	















lease14. Based on this knowledge, a double-layered skin construct was designed and constructed 
containing	specific	factors	to	stimulate	important	biological	processes	in	skin	regeneration	(Fig.	
1). The construct consisted of two layers: a collagenous epidermal layer harbouring heparin and 
FGF7	(which	stimulates	keratinocyte	proliferation),	and	a	porous	dermal	layer	consisting	of	type	
I	collagen	fibrils,	solubilised	elastin,	dermatan	sulfate,	heparin,	FGF2	and	VEGF.	This	molecularly-
defined	construct	was	characterised	and	evaluated	in vivo using a rat full-thickness wound mod-










Unless stated otherwise, all chemicals were purchased from Merck Chemicals (Darmstadt, 
Germany).	 Type	 I	 collagen	 fibrils	 were	 purified	 from	 bovine	 achilles	 tendon	 as	 described17. 
Solubilised	elastin	was	prepared	 from	equine	 ligamentum	nuchae	as	described9. Heparin and 
dermatan	sulfate	(DS)	were	purchased	from	Sigma	Chemical	Co.	(St	Louis,	MO,	USA).	Recombinant	 
rat FGF2 was produced in E. coli M15 PQE168 and recombinant rat VEGF-164 in P. pastoris GS11518. 









Preparation of the double-layered skin construct
The double-layered skin construct consisted of a dermal and epidermal layer. The dermal layer 
was prepared by freezing a suspension containing 0.64% (w/v) type I collagen and 0.16% (w/v) 
solubilised	elastin	in	0.25	M	acetic	acid	at	-20°C9,22, followed by lyophilising using a Zirbus lyophi-
liser	(Bad	Grund,	Germany).	The	resulting	scaffold	was	chemically	crosslinked	with	33	mM	1-eth-
yl-3-dimethyl	 aminopropyl	 carbodiimide	 (EDC)	 and	 6	mM	N-hydroxysuccinimide	 (NHS)	 in	 the	
presence of 0.375% (w/v) DS and 0.125% (w/v) heparin for 4 h in 50 mM 2-morpholinoethane 
sulphonic acid (pH 5.0) containing 40% ethanol, and washed with 0.1 M Na2HPO4, 1 M NaCl, 2 M 
NaCl, and demineralised water9.	Growth	factors	were	bound	to	the	dermal	layer	by	incubation	(1	
ml	per	8	mg	scaffold)	in	3.5	µg	FGF2/ml	and	3.5	µg	VEGF/ml	phosphate	buffered	saline	(PBS)	pH	
7.4	for	60	min,	followed	by	5x15	min	washings	with	PBS.
The epidermal layer was produced by air-drying a 0.8% type I collagen suspension in 0.25 M 
acetic	acid23, followed by EDC/NHS crosslinking in the presence of 0.5% heparin as described 
above.	The	epidermal	layer	(1	ml	solution	per	20	mg	scaffold)	was	incubated	in	0.5	µg	FGF7/ml	
PBS,	followed	by	5x15	min	washings	with	PBS.








6The ultrastructure of the constructs was analysed using scanning electron microscopy (SEM)10.
The extent of crosslinking	was	estimated	by	determination	of	the	amount	of	amine	groups,	which	
was analysed using 2,4,6-trinitrobenzene sulphonic acid24.




glycan content of the dermal layer was calculated by adding the numbers obtained for dermatan 
sulfate	and	heparin	(in	a	3:1	ratio).	
The amount of growth factor bound to the epidermal and dermal layer was determined by West-
ern	blotting25	using	antibodies	against	FGF2	(1:2000),	VEGF	(1:1000)	and	FGF7	(1:400).	Bound	
antibodies	were	 visualized	 using	 peroxidase-conjugated	 secondary	 antibodies	 and	 a	 chemilu-
minescent	detection	kit	 (ECL;	Amersham	Biosciences)	and	analysed	with	Gene	Tools	 software	
(Syngene,	Cambridge,	UK).	The	calibration	curves	ranged	from	0-100	ng	growth	factor.	Scaffolds	
without growth factors were taken as controls.






Figure 1 Design and rationale of the double-layered 
skin construct, consisting of an epidermal (film) layer 
and a dermal (porous) layer. The epidermal layer con-
tained type I collagen, heparin and recombinant rat 
FGF7. The dermal layer consisted of type I collagen, 
solubilised elastin, dermatan sulfate (DS), heparin and 
the recombinant rat growth factors FGF2 and VEGF. 
The construct was designed to resemble the architec-
ture of normal skin and to contain specific effector 
molecules. Heparin was added to the epidermal layer 
for hydration and growth factor binding, and FGF7 to 
stimulate keratinocyte migration and proliferation. 
Solubilised elastin was added to the dermal layer to in-
duce elastic fibre formation, DS and heparin to provide 
hydration and growth factor binding, VEGF to promote 
angiogenesis and FGF2 to enhance fibroblast prolifera-








Implantation of construct 
NIH	guidelines	for	the	care	and	use	of	laboratory	animals	(NIH	publication	85-23	Rev.	1985)	were	
observed.	The	study	was	approved	by	the	Ethics	Committee	of	the	Radboud	University	Nijme-
gen. Wistar rats (male, 3 months) were purchased from Harlan (Horst, The Netherlands). The 




postoperative	analgesia	was	given	 (injections	with	carprofen	 for	 two	days,	 twice	a	day).	Con-
structs	(1.5x1.5	cm)	were	disinfected	in	70%	ethanol	(3x30	min	and	one	overnight	incubation)	
and	washed	with	sterile	PBS	(6x60	min).	Two	full-thickness	wounds	of	1.5x1.5	cm,	including	the	
panniculus carnosus, were made on each side of the back of the rat and the constructs were 
placed in the wounds. The wounds were treated either with the double-layered skin construct, 
IntegraDRT	or	left	untreated.	The	double-layered	skin	construct	and	IntegraDRT	were	placed	in	
the	wound	in	such	a	way	that	they	fitted	exactly	and	touched	the	wound	edge,	without	overlap	
with the wound edge. The constructs were kept in place by 4 resorbable sutures (5-0 Vicryl). The 















son (EVG)26	and	a	Elastic	Masson’s	stain27. Phase contrast microscopy was used to study the lo-
cation	and	direction	of	newly-formed	collagen	fibres.	Histology	of	 the	explants	was	evaluated	
independently	 by	 at	 least	 two	experienced	 investigators.	 Sections	were	 scored	using	 a	 -	 (not	
present)	to	+++	(abundant)	scale.

















Characterisation of the constructs
Double-layered skin construct





The layers were individually crosslinked with EDC/NHS to covalently bind the glycosaminoglycans 
(94	µg	heparin/mg	epidermal	layer,	103	µg	dermatan	sulfate	+	heparin/mg	dermal	layer)	(Table	1).	
In the crosslinking process about 50% of the free amine groups were used (Table 1). The amount 
of	growth	factor	bound	to	each	layer	(0.2	µg	FGF7/mg	epidermal	layer	and	0.7	µg	FGF2	+	VEGF/
mg	dermal	layer)	was	determined	by	Western	Blotting	and	Gene	Tools	(Table	1).	
Table 1. Pore size and biochemical properties of the implanted constructs
Pore size and biochemical analysis of the epidermal layer, dermal layer and IntegraDRT. The amine group content 
was determined using 2,4,6-trinitrobenzene sulphonic acid24, the percentage crosslinking in comparison to non 
crosslinked scaffold is displayed between brackets. The glycosaminoglycan (heparin, DS and CS) content was deter-
mined using p-dimethyl-aminobenzoaldehyde17. Non-crosslinked collagen contained 298 ± 57 nmol amine groups/
mg scaffold Results are the mean ± SD of 3 independent experiments. Please note that no controls could be taken 







The	distribution	of	all	components	 in	the	construct	was	visualised	using	 immunostaining	 (Fig.	
2E-L), and was in accordance with the original design (Fig. 1). Both the epidermal and dermal 
layer	contained	type	I	collagen,	whereas	solubilised	elastin	was	only	present	in	the	dermal	layer.	
Heparin was distributed throughout the whole construct, with more intense staining of heparin 
in the epidermal layer. Dermatan sulfate, FGF2 and VEGF were found distributed throughout the 
dermal layer, the growth factors showing a more intense staining at the epidermal side. FGF7 was 








out the collagen layer (data not shown).
Figure 2  Electron microscopical and immunological evaluation of the double-layered skin construct and Inte-
graDRT. A-D: Scanning electron micrographs of the double-layered skin construct: (A) cross-section, the arrow 
indicates the epidermal layer, (B) glue layer, indicated by a double-headed arrow, (C) top of epidermal layer, and (D) 
dermal layer. E-L: Immunolocalisation of (E) type I collagen, (F) heparin, (G) FGF7, (H) negative control, (I) elastin, 
(J) dermatan sulfate, (K) FGF2 and (L) VEGF. The epidermal (top) layer is indicated by a dashed line. M-P: Scanning 
electron micrographs of IntegraDRT: (M) cross-section, (N) close-up of M, (O) top of (silicon) layer and (P) top of 
dermal layer. In M and N, # indicates the silicon layer and * the dermal collagen layer. Bar is 100 µm in A, D, E-N 




6Evaluation of constructs in full thickness wounds 
No	infections	or	illnesses	were	observed	in	the	rats	and	they	stayed	healthy	without	considerable	















a larger area (90 ± 8% of the original wound area) in comparison to the untreated wound (65 ± 
23%). IntegraDRT had 84 ± 16% of the original wound area (Fig. 3B). 
At	day	14,	the	double-layered	skin	construct	had	significantly	less	contraction	than	IntegraDRT	
and	the	untreated	wound	(p<0.008	and p<0.002	respectively).	The	double-layered	skin	construct	
(80 ± 16%) occupied a larger area than IntegraDRT (47 ± 19%) and the untreated wound (39 ± 
22%) (Fig. 3A, B). 
At day 28 and 112, the remaining wound areas for all treatments ranged from 12-31% and no 
major	differences	were	observed	between	the	groups.
Figure 3 Degree of wound contraction as ana-
lysed by the remaining wound area. A) Mac-
roscopical images of the wound area at day 0 
and day 14. B) Quantitative data of remaining 
wound area. Values are mean ± SD (n=4). At 
day 7, a significant difference was found be-
tween the untreated wound versus the double-
layered skin construct (p < 0.05*). At day 14, 
the double layered skin construct was found 
to have significantly less contraction than In-















ered skin construct and the untreated wound showed some granulocytes, whereas larger num-
bers	were	observed	in	IntegraDRT.	No	differences	were	observed	with	respect	to	macrophages	
and	fibroblasts.





At day 112, all three groups had a fully developed epidermis, but no rete ridge structures were 
present in the newly-formed epidermis. The thickness of the epidermis (measured as number of 
cell-layers)	was	found	to	be	variable	within	each	group,	but	no	major	differences	were	observed.	
Granulocytes were absent. Compared to normal skin, slightly more macrophages appeared to be 
present in the healed area of all three groups (Table 2 and Fig. 4A). Structures resembling hair 
follicles and sebaceous glands were observed in the double-layered skin construct and the un-




Table 2. Cellular response in wound area after treatment, compared to normal skin.
The cells were scored from absent (-) to abundantly present (+++). The absolute numbers of granulocytes are much 
lower than for phagocytic cells. * Phagocytic cells include macrophages and giant cells. 
# The myofibroblasts were visualised using an antibody against smooth muscle actin. More myofibroblasts were 











observed at day 112 and in normal skin.
Construct components
Collagen: Immunostaining for construct type I collagen showed that at day 7 most of the material 
of	the	double-layered	skin	construct	and	IntegraDRT	was	still	present	(Table	3).	At	day	14,	colla-





seen at days 28 and 112.
Glycosaminoglycans: At day 7 and 14, heparin was mainly visible in the epidermal layer of the 
double-layered	skin	construct,	whereas	dermatan	sulfate	was	only	found	on	the	collagen	fibrils	
of the dermal layer (data not shown). At day 28, hardly any staining was observed of construct 
Figure 4 Histological images of the centre of the wound area at day 112. 
A) Haematoxylin & eosin staining (HE), B) Elastic Masson’s staining (EM), C) phase-contrast (PH) of the double-layered 
skin construct, IntegraDRT and untreated wound compared to normal skin. 
A) a closed epidermis was present in all cases and no differences were found in the number of cell layers. Rete ridge 
structures were absent. The dermis of the double-layered skin construct, IntegraDRT and the untreated wound showed 
higher numbers of cells than the normal skin (cells are blue). B) In the double-layered skin construct and the untreated 
wound, hair follicle-like and gland-like structures (arrows) were observed (also visible in C). Mature collagen fibres 
stain red, whereas the newly formed fibres are light blue. C) Phase contrast microscopy revealed that collagen fibres 
were more randomly oriented in the double-layered skin construct and untreated wound than in IntegraDRT. Bar in A 















three groups at day 112. At day 7 and 14, the double-layered skin construct and the untreated 




bundles in IntegraDRT were found to be more aligned (Fig. 4C). When comparing the results of 
the treatments with normal skin, the double-layered skin construct and the untreated wound 
resembled the normal skin at day 112 more closely than IntegraDRT. 
Type III collagen: At day 7, the double-layered skin construct contained a moderate amount of rat 
type III collagen, whereas IntegraDRT and the untreated wound contained less. From day 14 on, 
a moderate amount was found in all three groups.
Elastin:	The	amount	of	elastic	fibres	increased	with	time,	being	most	abundant	in	the	double-
layered skin construct at day 112 (Fig. 5). At day 7, 14 and 28, IntegraDRT contained the least 
elastic	fibres,	while	the	untreated	wound	had	the	same	or	more	elastic	fibres	than	the	double-
layered skin construct. 
At day 7, 14 and 28, the least dermatan sulfate was found in IntegraDRT. At day 28, the dou-
ble-layered skin construct contained most dermatan sulfate, whereas at day 112, the untreated 
wound contained most dermatan sulfate, similar to normal skin.
Table 3. Overview of immunostaining for matrix molecules in wound area after treatment, compared to normal skin.





At day 7 and 14, the double-layered skin construct and the untreated wound contained more 
blood vessels than IntegraDRT (Fig. 6). The blood vessels already invaded the double-layered 
skin construct at day 7, whereas hardly any blood vessels were found inside the collagen layer 
of	IntegraDRT.	At	day	28,	the	double-layered	skin	construct	still	had	many	blood	vessels	present,	
whereas the untreated wound and IntegraDRT contained a moderate amount. The blood ves-
sels were evenly distributed throughout the wound area. At day 112, all groups had moderate 
amounts of blood vessels present in the wound area. These were smaller, but more abundant 
than in normal skin.
Figure 5 (Immuno)histochemical evaluation 
of newly formed elastin at day 112, as anal-
ysed with (A) Immunostaining for elastin and 
(B) Elastin von Gieson staining with a magni-
fication of an area located directly under the 
epidermis. The double-layered skin construct 
showed elastin around blood vessels and hair 
follicle-like structures, and a large amount 
of elastic fibres throughout the upper der-
mis. IntegraDRT and the untreated wound 
contained a moderate amount of elastic fi-
bres that were mainly located in the upper 
part of the dermis. The untreated wound 
also showed elastic fibres surrounding hair 
follicle-like structures. Normal skin showed 
elastic fibres around blood vessels and hair 
follicles in the dermis. Arrows indicate elastic 
fibres. Bar (A) is 25 µm, Bar (B) is 1 µm. 
Figure 6 Presence of blood vessels in the wound 
area as visualised using an antibody against 
type IV collagen. The top of the dermis/epider-
mal layer is indicated by a dashed line. In the 
double-layered skin construct and untreated 
wound, more blood vessels were present on 
day 7 and 14, and they had penetrated more 
towards the epidermis in comparison to Inte-
graDRT. On day 28, the double-layered skin 
construct possessed more blood vessels than 
IntegraDRT and the untreated wound. On day 
112, all treatments showed a similar number 
of blood vessels, more abundant and with a 
smaller diameter compared to normal skin. 












VEGF throughout the porous dermal layer. The double-layered skin construct was developed to 
accelerate and improve wound healing. In the clinic, acellular constructs may be preferred over 
cellular constructs for their ease of handling, transport and storage. 








the	construct	may	have	prevented	 the	 remaining	myofibroblasts	 from	contracting	 the	wound	
area.	When	cells	are	randomly	bound	to	the	scaffold	the	sum	of	the	contracting	forces	is	near	
zero30. The FGF2 present in the double-layered skin construct (and not in IntegraDRT) may have 
been	 instrumental	 in	diminishing	 the	amount	of	myofibroblasts	present	on	day	14.	However,	
at	day	28	more	myofibroblasts	were	found	than	at	day	14	in	the	double-layered	skin	construct.	
FGF2 has a short life span which is increased by binding to heparin31,	but	after	28	days	most	of	
the	construct	was	degraded,	and	a	lack	of	FGF2	may	eventually	have	revoked	the	active	inhibi-




of cells8,10. This was also seen in the double-layered skin construct, whereas IntegraDRT and the 
untreated	wound	showed	less	influx	of	e.g.	granulocytes	at	day	7.	Whereas	at	day	14,	IntegraDRT	
displayed	 the	most	granulocyte	 influx.	 For	good	and	 rapid	wound	healing,	 infiltration	of	 cells	





In	 commercially	 available	 acellular	 skin	 substitutes,	 it	 takes	 several	weeks	 to	 develop	 a	well-
developed	vasculature.	This	results	in	impaired	wound	healing,	due	to	a	lack	of	oxygen,	nutrients	







710. In the double-layered skin construct, many blood vessels were found on day 7, in contrast to 
IntegraDRT	which	did	not	develop	a	similar	amount	of	blood	vessels	on	any	of	the	time-points	
examined.	Moiemen	et	al.	 found	that	 IntegraDRT	was	only	 fully	vascularised	after	4	weeks	 in	
humans35.	This	is	in	line	with	our	findings	that	it	took	until	day	28	before	the	newly-formed	vas-
culature	in	IntegraDRT	had	reached	the	top	of	construct.	The	addition	of	growth	factors	 in	an	
acellular construct may thus greatly improve angiogenesis.
The	orientation	of	collagen	fibres	in	normal	skin	has	a	basket	weave	pattern,	whereas	in	scars	the	
fibres	are	very	much	aligned	in	a	parallel	way36. We and others have seen that the micro archi-
tecture	of	the	original	scaffold	influences	the	orientation	of	newly-formed	collagen	fibrils37,38. In 
the double-layered skin construct, the dermal layer had large randomly oriented pores to allow 
random	collagen	deposition,	which	indeed	occurred,	as	indicated	by	phase	contrast	microscopy.
An	 interesting	 feature	was	 the	presence	of	structures	 resembling	hair	 follicles	and	sebaceous	
glands in the double-layered skin construct and untreated wound at day 112. These structures 
were mainly found at the outer region of the healed wound, though some were present in the 
centre. Stem cells from the hair follicles in the vicinity of the wound edges probably migrate into 
the wound bed and proliferate to form a new hair follicle. This was not demonstrated by tech-
niques.	The	group	of	Ito	et	all	demonstrated	that	in	adult	mice,	de	novo	hair	follicle	formation	
was	found	after	an	excision	of	1	cm2	full-thickness	back	skin39. Growth factors (e.g. epidermal 
growth factor and FGF) are involved in hair follicle sebaceous gland development40. Further re-
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biomaterial for skin replacement, mimicking the natural environment.  
In chapter 1,	an	overview	is	given	of	some	major	natural	components	and	their	application	for	
the	construction	of	molecularly	defined	scaffolds	for	tissue	engineering.		To	enhance	the	regen-
eration	process	growth	factors	are	needed.	In	chapter 2, the cloning of rat VEGF-164, its large 
scale	production	in	a	Pichia pastoris expression	system	is	described.	VEGF-164	was	purified	using	
a	heparin	column	and	shown	to	be	biologically	active.
Preparation and evaluation of collagen–based scaffolds for tissue engineering
Using	purified	components,	tailor-made	scaffolds	were	prepared	to	evaluate	the	effect	of	each	





To	create	a	scaffold	 that	does	not	calcify	 in vivo,	purified	elastin	fibres	were	solubilised	using	
oxalic	acid	hydrolysis.	Collagen-solubilised	elastin	scaffolds	did	indeed	not	calcify	 in	the	young	
rat model as described in chapter 4.	The	solubilised	elastin	was	mainly	present	in	the	scaffold	as	
globular	structures	that	were	incorporated	in	the	scaffold.	These	scaffolds	showed	more	elastic	
fibre	 formation	and	angiogenesis	 in	comparison	to	 the	collagen-elastic	fibre	scaffold.	Chapter 
5	describes	the	contribution	of	heparin	and	growth	factors	 in	 inducing	angiogenesis	 in	tissue-
engineered	constructs.	Five	scaffolds	composed	of	type	I	collagen,	collagen-heparin	and/or	FGF2	
and/or VEGF were made, characterized and implanted subcutaneously in a Wistar rat model. The 
scaffolds	with	heparin	and	both	growth	factors	gave	rise	to	mature	blood	vessels	after	just	7	days.




7developed.	 The	 construct	was	 composed	of	 two	 layers;	 the	upper	 epidermal	 layer	 consisting	
of	a	type	I	collagen	film	with	heparin	and	FGF-7,	and	a	porous	dermal	layer	consisting	of	type	
I	collagen-solubilised	elastin,	heparin,	dermatan	sulphate,	VEGF-164	and	FGF2	as	described	in	











































that	FGF2	decreases	contraction	by	inhibiting	the	formation	of	myofibroblasts3. In the double-
layered	skin	construct	prepared	here,	FGF-2	may	be	released/degraded	too	quickly.	An	idea	is	to	
aim	for	a	sustained	release	of	the	FGF-2	and	study	if	this	decreases	the	contraction.	Also	it	was	
found that FGF-2 regulates the melanocyte viability4	and	a	sustained	release	might	lead	to	better	
skin	color.	In	literature	it	is	described	that	TGF-β2	induces	hair	follicle	morphogenesis	and	that	
TGF-β	decreases	contraction6. Adding these growth factors to the construct might lead to a 
better	outcome	for	the	patient.
For future study, it may be possible to incorporate biocapsules like lyophilisomes made from 
solubilised	 elastin	 in	 the	 skin	 construct7.	 For	 example,	 anti-bacterial	 compounds	 (silver	 or	





Pig skin resembles human skin more. It is important to study how the developed construct 
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Nabootsen van het natuurlijke weefsel met zuivere bestanddelen
Het	 doel	 van	tissue	 engineering	 is	 het	 herstellen/vervangen	 van	 beschadigde	weefsels	 of	 or-
ganen. Biomaterialen die ontwikkeld worden voor dit doel zijn vaak gebaseerd op natuurlijke 
moleculen	 (zoals	 collageen)	met	 of	 zonder	 cellen.	Het	 heeft	de	 voorkeur	 om	een	 product	 te	
maken	dat	direct	beschikbaar	is	voor	de	patiënt,	want	cellen	toevoegen	aan	een	biomateriaal	
is	een	kostbare	zaak	en	autologe	cellen	zijn	niet	direct	voorhanden	voor	een	patient1. Mijn doel 
is om acellulaire biomaterialen te maken die zo veel mogelijk overeenkomen met het vereiste 
weefsel	 en	 die	 cellen	 aantrekken	om	het	 gewenste	 regeneratieproces	 in	 gang	 te	 zetten,	 bijv.	
angiogenese.	Om	een	dergelijk	biomateriaal	te	ontwikkelen	is	het	nodig	om	te	weten	wat	het	
effect	 is	van	 iedere	component	afzonderlijk.	Dit	 is	alleen	mogelijk	als	deze	biomaterialen	qua	
samenstelling	goed	beheerst	kunnen	worden,	zoals	door	het	gebruik	van	gezuiverde	extracel-
lulaire	matrixbouwstenen.	Het	doel	van	deze	thesis	is	om	een	nieuw	biomateriaal		-zonder	cel-
len- te ontwerpen, te maken en te evalueren voor gebruik als huidvervanger, en gebaseerd op de 
natuurlijke cellulaire omgeving.
In hoofdstuk 1 staat een overzicht van alle zuivere natuurlijke componenten die gebruikt kunnen 
worden	bij	het	maken	van	een	construct	voor	tissue	engineering.	Om	regeneratieprocessen	op	
gang	te	brengen	zijn	groeifactoren	nodig.	Het	kloneren	van	rat	VEGF-164	en	de	productie	hiervan	
in het Pichia pastoris fermentor systeem wordt beschreven in hoofdstuk 2. De grote hoeveelheid 
aan	geproduceerd	VEGF-164	werd	gezuiverd	via	heparine-affiniteitschromatografie	en	bleek	bio-
logisch	actief.
Bereiding en evaluatie van op collageen gebaseerde biomaterialen voor tissue engineering
Met	de	gezuiverde	componenten	zijn	verschillende	biomaterialen	gemaakt	om	zo	het	effect	van	
de verschillende componenten te kunnen bestuderen. In hoofdstuk 3 staat een beschrijving van 








ven in hoofdstuk 4.	Het	oplosbaar	elastine	vormde	ook	ronde	structuren	die	verbonden	waren	
aan	het	collageen	van	de	matrix.	Deze	matrices	 lieten	meer	angiogenese	en	nieuw	gevormde	
elastische	vezels	zien	dan	de	matrices	met	elastinevezels.	In	hoofdstuk 5 wordt de bijdrage van 
heparine	en	groeifactoren	in	het	stimuleren	van	angiogenese	in	tissue-engineered	constructen	




7en/of FGF-2 en/of VEGF-164 zijn gemaakt, geanalyseerd en onderhuids geïmplanteerd in Wistar 
ratten.	In	de	matrices	met	heparine	en	beide	groeifactoren	was	na	7	dagen	al	een	ontwikkeld	
vaatbed aanwezig.
Moleculair gedefinieerde constructen voor huid tissue engineering
Door	de	 resultaten	hierboven	 te	 combineren	 is	 er	een	moleculair	 gedefinieerd	huidconstruct	
ontworpen en ontwikkeld. Het construct dat beschreven is in hoofdstuk 6 bestaat uit twee lagen; 
de	bovenste	epidermale	laag	bestaat	uit	een	type	I	collageen	film	met	heparine	en	FGF-7	en	de	
poreuze	dermale	laag	bestaat	uit	een	type	I	collageen,	oplosbaar	elastine,	heparine,	dermatan	
sulfaat, FGF-2 en VEGF-164. Na analyse van het construct is het geïmplanteerd in een acuut 




weinig verschillen gevonden ten opzichte van de onbehandelde wond.
Algemene conclusie
Zuivere componenten werden geproduceerd, in het bijzonder VEGF-164. Deze componenten 
werden	 gebruikt	 om	 moleculair	 gedefinieerde	 matrices	 te	 maken	 waarbij	 de	 bijdrage	 van	 
individuele	componenten	 is	bestudeerd.	Om	verkalking	te	voorkomen	en	vroege	vorming	van	
elastische	vezels	 te	bewerkstelligen,	moet	oplosbaar	elastine	worden	toegevoegd.	Om	vroege	
bloedvatvorming te induceren, kunnen FGF-2 en VEGF aan een construct toegevoegd worden. In 
het	moleculair	gedefinieerde	huidconstruct	is	de	bijdrage	van	deze	componenten	aangetoond.	
Het	construct	liet	meer	bloedvaten	en	minder	contractie	op	een	vroeg	tijdstip	zien.	Deze	resul-
taten zijn veelbelovend, maar toch is dit nog niet het ideale construct voor de behandeling van 
een acute wond.
Het	onderzoek	in	deze	thesis	laat	zien	dat	het	mogelijk	is	om	complexe	tissue	engineered	ma-






















Daarom zouden we moeten streven naar een construct dat de juiste processen opstart, waarna 
het lichaam het benodigde weefsel zelf gaat aanmaken. Het is erg interessant om het wondge-
nezingsproces in een embryo te analyseren, omdat een vroeg embryonale wond geneest zonder 




kunnen voldoen. Dit maakt stap van de research naar het bedrijfsleven en de kliniek moeilijk. 
Voor	 commerciële	 haalbaarheid	 is	 het	 beter	 om	het	 construct	 zo	 simpel	mogelijk	 te	 houden	
(“keep	it	simple”	principe).
Voor	de	toekomst	van	het	moleculair	gedefinieerde	dubbel-laags	huidconstruct	zou	het	interes-
sant zijn om te zien hoe aanpassingen aan het construct de resultaten beïnvloeden, bijvoor-
beeld	door	de	hoeveelheid	en	de	ratio	van	de	groeifactoren	te	veranderen.	 In	de	 literatuur	 is	
beschreven	 dat	 FGF-2	 contractie	 vermindert	 door	myofibroblast	 vorming	 te	 remmen3. In het 
dubbel-laags construct kan het FGF-2 mogelijk te snel vrijkomen of afgebroken worden. Een con-
stante	afgifte	en	verdere	bescherming	van	FGF-2	zou	contractie	mogelijk	 langer	verminderen.	
Daarnaast is ook gebleken dat FGF-2 de levensvatbaarheid van melanocyten reguleert4 en zou 




elastine	toe	te	voegen	aan	het	huidconstruct7. Deze capsules kunnen gevuld worden met bijvoor-
beeld	antibacteriële	componenten	(zilver	of	β-defensines)	en	zo	zouden	infecties	kunnen	worden	
onderdrukt in chronische wonden8,9.	De	antibacteriële	componenten	worden	vrijgegeven	als	de	
microcapsules worden afgebroken. Dit is natuurlijk niet een nabootsing van natuurlijk weefsel, 
maar kan wel een bijdrage leveren aan een goede wondgenezing.
Voordat een dergelijk construct beschikbaar is voor gebruik in de kliniek, moeten er meer proef-
dierexperimenten	 uitgevoerd	worden.	 De	 rattenhuid	 verschilt	 van	 die	 van	 de	mens	 en	 bevat	 
bijvoorbeeld	een	spierlaag	die	de	mens	niet	heeft.	De	huid	van	een	varken	lijkt	meer	op	de	huid	
van de mens. Het is erg belangrijk om te zien hoe een construct reageert in een ander dier. Veel 
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Figure 1. Macroscopic (A, B) and scanning electron microscopical images (C, D) of dense films (A, C) and porous 
scaffolds (B, D). Bar is 1 cm in A, B, and 100 µm in C, D 33. Figure reproduced from 33 with permission.
Chapter 1 Mimicking the micro-environment
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Figure 4. Macroscopical (A) and immunohistochemical evaluation of the scaffolds explanted at day 7 (B, C).
A)  Macroscopical evaluation of a non-implanted scaffold at day 0 and explants at day 7 (COL, COLHV and COLHFV). 
Note the red appearance of the COLHFV scaffold.
B)  Immunohistochemical evaluation using type IV collagen staining of the scaffolds explanted at day 7. COLHFV 
showed the most and largest area of blood vessels compared to COLHV, COLHF and COLH. No blood vessels were 
found in COL at this time point. 
C)  Immunohistochemical evaluation using smooth muscle actin staining of scaffolds explanted at day 7. COLHFV 
displayed the largest percentage of mature blood vessels compared to COLHV, COLHF and COLH. Arrows indicate 
SMA-positive blood vessels. Bar is 50 µm.
Figure 6. Immunohistochemical analysis of HIF1-α staining of cells in the scaffolds at day 3, 7 and 21.
A)  Photographs of COLHFV scaffold at day 3 and 7. COLHFV showed many hypoxic cells at day 3 and few at day 7. 
Inserts show that HIF1-α predominantly stains the nuclei of cells. Positive cells stain black and negative cells stain 
blue. Bar is 10 µm.
B)  Statistical analysis of the percentages of HIF1-α positive cells. At day 7 and 21, COLHFV had significantly less 
hypoxic cells than all other scaffolds. *p<0.05.
Chapter 5 Increased angiogenesis and blood vessel maturation in acellular 
collagen-heparin scaffolds containing both FGF2 and VEGF
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Colour	figures
8Chapter 6 Design and in vivo evaluation of a molecularly-defined acellular 
skin construct
Figure 3 Degree of wound contraction as analysed by the remaining wound area. A) Macroscopical images of the 
wound area at day 0 and day 14. B) Quantitative data of remaining wound area. Values are mean ± SD (n=4). At 
day 7, a significant difference was found between the untreated wound versus the double-layered skin construct 
(p < 0.05*). At day 14, the double layered skin construct was found to have significantly less contraction than Inte-
graDRT and the untreated wound (p<0.008^ and p<0.002#, respectively).
Figure 4 Histological images of the centre of the wound area at day 112. 
A) Haematoxylin & eosin staining (HE), B) Elastic Masson’s staining (EM), C) phase-contrast (PH) of the double-layered 
skin construct, IntegraDRT and untreated wound compared to normal skin. 
A) a closed epidermis was present in all cases and no differences were found in the number of cell layers. Rete ridge 
structures were absent. The dermis of the double-layered skin construct, IntegraDRT and the untreated wound showed 
higher numbers of cells than the normal skin (cells are blue). B) In the double-layered skin construct and the untreated 
wound, hair follicle-like and gland-like structures (arrows) were observed (also visible in C). Mature collagen fibres 
stain red, whereas the newly formed fibres are light blue. C) Phase contrast microscopy revealed that collagen fibres 
were more randomly oriented in the double-layered skin construct and untreated wound than in IntegraDRT. Bar in A 
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